Metabolism xxx (xxxx) xxx



Review

Contents lists available at ScienceDirect

Metabolism



journal homepage: www.journals.elsevier.com/metabolism

Epidemiology of sarcopenia: Prevalence, risk factors, and consequences

Shuai Yuan^a, Susanna C. Larsson^{a,b,*}

^a Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
 ^b Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

ARTICLE INFO

Keywords: Meta-analysis Muscle mass Prevalence Review Risk factors Sarcopenia

ABSTRACT

Sarcopenia is a geriatric condition featured by a progressive loss of muscle mass and function and associated with various adverse health outcomes. In this review, we aimed to summarize the epidemiological features of sarcopenia as well as consequences and risk factors of the disease. We performed a systematic review of metaanalysis on sarcopenia to collect data. The prevalence of sarcopenia varied between studies and depending on definition used. Sarcopenia was estimated to influence 10 %–16 % of the elderly worldwide. The prevalence of sarcopenia was higher among patients compared to general populations. The prevalence of sarcopenia is associated with a high risk of a wide range of adverse health outcomes, including poor overall and disease-progression free survival rate, postoperative complications, and longer hospitalization in patients with different medical situations as well as falls and fracture, metabolic disorders, cognitive impairment, and mortality in general populations. Physical inactivity, malnutrition, smoking, extreme sleep duration, and diabetes were associated with an increased risk of sarcopenia. High-quality cohort, omics, and Mendelian randomization studies are needed to deeply understand the etiological basis of sarcopenia.

1. Introduction

Sarcopenia is a geriatric condition featured by a progressive loss of muscle mass and function and has been associated with several adverse health outcomes, including fracture, functional decline, and mortality [1]. Except commonly affecting the elderly, it can also onset in mid-life [1] and become prevalent among certain populations, such as patients with cancer [2], kidney dysfunction [3], liver disease [4], and metabolic disorders [5]. Sarcopenia is also an important prognostic indicator for survival and clinical complications in these patients [2–5]. Even though sarcopenia has received attention of intense research, it is poorly concluded about its epidemiological features, risk factors, and complications. This review aims to summarize the epidemiological features of sarcopenia as well as consequences and risk factors of the disease.

2. Materials and methods

To summarize available data in a comprehensive way, we performed a systematic review of meta-analysis on sarcopenia (Fig. 1). We searched "sarcopenia" and "meta" in the PubMed database and obtained 726 studies after removing publications before 2010 when most definitions of sarcopenia were published [1]. Two authors independently reviewed the 726 studies and classified included studies into two categories that are studies on risk factors and on consequences. We excluded studies on sarcopenia components instead of sarcopenia as a binary phenotype, studies on obesity sarcopenia, and studies without performed metaanalysis. We extracted information on title, PubMed ID, publication year, first author, population (general population or patients), number of studies included in meta-analysis, total sample size, prevalence of sarcopenia, the associations, and heterogeneity.

3. Results

We included 130 studies in the systematic review of risk factors and consequences of sarcopenia, among which 25 and 109 studies were on risk factor and consequences, respectively. Although this review did not aim to estimate prevalence of sarcopenia in a comprehensive way, we extracted corresponding data to complement the current evidence of prevalence of sarcopenia shown in previous studies, especially among patients with different medical conditions.

* Corresponding author at: Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. *E-mail address:* susanna.larsson@surgsci.uu.se (S.C. Larsson).

https://doi.org/10.1016/j.metabol.2023.155533

Received 27 December 2022; Received in revised form 21 February 2023; Accepted 4 March 2023 Available online 11 March 2023 0026-0495/© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).



Fig. 1. Flow chart of the systematic review.

3.1. Definitions and prevalence of sarcopenia

Before 2010 when the definition of sarcopenia was proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) [6], low muscle mass was used to define the disease [7], which is partial and could not reflect muscle function. Nowadays, the most commonly used definition of sarcopenia is that recommended by EWGSOP, which was updated as EWGSOP2 in 2019 [8]. This definition was supported by the Asian Working Group on Sarcopenia albeit with different cutoffs for Asians [9] and this is the only definition endorsed by a range of international scientific societies [1]. There are also other definitions for sarcopenia, including the International Working Group on Sarcopenia (IWGS) [10] and the Foundation for the National Institute of Health (FNIH) [11]. These definitions have been summarized in Table 1. Sarcopenia has now been formally recognized as a muscle disease in the International Classification of Disease (ICD-10: M62 [84]) [12].

Even though recent studies used comparatively consistent definitions for sarcopenia, different cut-offs and applied measurements (i.e., bioelectrical impedance (BIA) or dual-energy x-ray absorptiometry (DXA)) make it still difficult to estimate disease prevalence in a homogeneous manner, which is reflected by a wide range of prevalence of sarcopenia in the majority of meta-analyses (Supplementary Table 1). Despite this, there are several meta-analyses with comprehensively collected data on the prevalence of sarcopenia by commonly used definitions, which is informative to understand the epidemiological features of sarcopenia.

The prevalence of sarcopenia varies largely between studies and depends on definition used to define the disease (Table 2) [13,14]. In the systematic review by Nascimento PR et al. [13], the global prevalence of sarcopenia ranged from 5 % (95 % confidence interval [CI] 1 %-10 %) for EWGSOP2 to 17 % (95 % CI 11 %-23 %) for IWGS among the elderly. However, the highest prevalence of sarcopenia was observed for EWG-SOP (22 %, 95 % CI 20 %-25 %) and the lowest was for FNIH (11 %, 95 % CI 9 %–14 %) in the study by Petermann-Rocha F et al. [14]. The pooled prevalence of all definitions was around 10 % (95 % CI 7 %-12 %) in Nascimento PR et al. study [13] and 16 % (95 % CI 15 %-17 %) in Petermann-Rocha F et al. study [14]. Even though two studies were based on generally healthy populations, like community-dwelling elderlies, the estimated prevalence of sarcopenia differed, and the reasons for this heterogeneity remain unclear. In another meta-analysis of 58,404 community-dwelling participants aged 60 years and older, the overall global prevalence of sarcopenia was estimated to be 10 % and

found to be slightly higher when using BIA compared to DXA to measure muscle quantity [15].

The prevalence of sarcopenia was much higher in different patient groups compared to the general population (Table 3). In the included studies reporting pooled prevalence, the prevalence of sarcopenia ranged from 18 % in patients with diabetes [5] to 66 % in patients with unresectable esophageal cancer [16]. A high prevalence of sarcopenia was also observed in patients with kidney and liver disease [4,17], who need surgery [18], and with different site-specific cancers [2,19–23].

3.2. Consequences of sarcopenia

In studies involving patients with different medical conditions, mortality, survival, and postoperative complications were the primarily studied and observed outcomes (Supplementary Table 1). Overall, baseline sarcopenia or preoperative sarcopenia was associated with an increased risk of short- and long-term mortality, poor overall and progression-free survival rate, overall and severe complications, postoperative infection, and prolonged hospitalization in most included studies (Supplementary Table 1). However, the risks varied between different patient groups concerning mortality and survival rate (Fig. 2) and other consequences. The all-cause mortality of sarcopenia was the highest among patients with emergency laparotomy (odds ratio [OR] = 3.50, 95 % CI 2.54-4.81) [24] and the lowest among patients with radical cystectomy (hazard ratio [HR] = 1.41, 95 % CI 1.22-1.62) [25] (Fig. 2). Likewise, the risk of poor overall survival was observed to be highest among patients with lung cancer (OR = 3.07, 95 % CI 2.45 - 3.85) and to be lowest among patients with esophageal cancer (HR = 1.12, 95 % CI 1.04-1.20) (Fig. 2). Of note, even though the comparison of the magnitude of the associations might reflect seriousness of sarcopenia in the risk of death and poor survival among different patient groups, it should be interpreted with caution for following reasons. First, there were moderate to high heterogeneity between studies in these combined associations. Second, certain associations with large CI due to small sample sizes were imprecise. Third, some studies were mainly based on a retrospective design where measurement error of sarcopenia might bias the results. Last but not least, the associations might be largely influenced by used definitions of sarcopenia and possibly by different measurements of muscle mass, which confined the comparability of these associations. Sarcopenia was additionally associated with an increased risk of disease progression in patients with liver diseases [26,27], an increased risk of osteoporosis in individuals with chronic obstructive

S. Yuan and S.C. Larsson

Commonly used definitions of sarcopenia and cut-offs of indicators after 2010.

Classification	Definition	Muscle mass	Muscle strength		
		ASM (kg) or ASM/height ² (kg/m ²)	Grip strength (kg)	Gait speed (m/s)	
EWGSOP	 * Low muscle mass * Low grip strength or slow gait speed 	Based on BIA:	Men < 30 Women < 20	Men and women < 0.8	
	0 r · · · 0 · · · · · · · · ·	Men $<$ 8.31–10.75 kg/m ²			
		Women < 6.42–6.75 kg/m ²			
		Based on DXA:			
		Men < 7.23–7.26 kg/m ²			
		Women $< 5.45 - 5.67 \text{ kg/m}^2$			
EWGSOP2	* Low muscle mass	Based on DXA:	Men < 27	Men and women < 0.8	
	* Low grip strength		Women < 16		
		$Men < 7.0 \text{ kg/m}^2$			
		Women $< 5.5 \text{ kg/m}^2$			
AWGS	* Low muscle mass	Based on BIA:	Men < 26	Men and women < 0.8	
	* Low grip strength or slow gait speed		Women < 18		
		$Mem < 7.0 \text{ kg/m}$ $Momon < 5.7 \ln(m^2)$			
		Based on DVA:			
		based on DAA.			
		$Men < 7.0 \text{ kg/m}^2$			
		Women $< 5.4 \text{ kg/m}^2$			
IWGS	* Low muscle mass	Based on BIA:	-	Men and women < 1.0	
	 * Slow gait speed 				
		$Men < 7.23 \text{ kg/m}^2$			
		Women $< 5.67 \text{ kg/m}^2$			
		Based on DXA:			
		$Men < 7.23 \text{ kg/m}^2$			
		Women $< 5.67 \text{ kg/m}^2$			
FNIH	* Low muscle mass	Men < 19.75 kg	Men < 26	Men and women < 0.8	
	* Low grip strength	Women $< 15.02 \text{ kg}$	Women < 16		

AWGS, Asian Working Group for Sarcopenia; BIA, bioelectrical impedance; DXA, dual-energy x-ray absorptiometry; EWGSOP, European Working Group on Sarcopenia in Older People; EWGSOP2, European Working Group on Sarcopenia in Older People 2; FNIH, Foundation for the National Institute of Health; IWGS, International Working Group on Sarcopenia.

pulmonary disease [28], and an increased risk of major adverse cardiovascular outcomes and heart failure-related hospitalization in patients with coronary artery disease [29].

The focus of consequences of sarcopenia differed between studies in patients and general populations. With exception for an increased risk of mortality, sarcopenia was further associated with a high risk of cognitive impairment, osteoporosis, falls, fracture, functional decline, hospitalization, metabolic syndrome, diabetes, nonalcoholic liver disease, liver fibrosis, hypertension, depression, and dysphagia among general populations (Table 4). Even though most these associations were based on meta-analyses of cohort studies, the causality remained uncertain due to residual confounding and measurement errors. In addition, the associations may differ using different definitions of sarcopenia, which may also partly explain the high heterogeneity in certain studies. However, falls appeared to be robustly associated with sarcopenia regardless of definition used for sarcopenia [30].

3.3. Risk factors for sarcopenia

There are comparatively fewer studies exploring the risk factors for sarcopenia (Supplementary Table 2). Overall, evidence of these studies was low with a few prospective cohort studies. Thus, the associations reported in previous meta-analysis of risk factors for sarcopenia (Table 5) should be interpreted with caution due to the possibility of reverse causality and confounding affecting the results.

Overweight or obesity measured by body mass index was inversely associated with the risk of sarcopenia [31–33]. However, this inverse association might be biased by muscle mass, which is positively correlated with body mass index [31]. After adjustment for muscle quantity, higher body mass index was associated with an increased risk of sarcopenia [31]. This association was partly in line with a positive association between visceral fat area (a more precise indicator of fat accumulation) and the risk of sarcopenia [5], which indicates that purely excessive fat is not a protective factor for sarcopenia. Instead, sarcopenic obesity affecting 11 % of global older adults has been associated with various adverse outcomes [34].

Among lifestyle factors, physical activity and nutritional status determined by dietary intake or nutrient supplementation appear to be associated with the risk of sarcopenia [5,32,35,36]. In addition, a mixed promotion of physical activity and nutritional supplementation may also be an effective intervention in sarcopenic patients [37,38]. To detail corresponding prevention and therapeutic strategies, studies on comparative effects of individual and combinations of different types of physical activities and dietary patterns are warranted. Alcohol consumption was not associated with the risk of sarcopenia [32,39,40]. Smoking was associated with an increased risk of sarcopenia in a meta-analysis of 29 studies with moderate heterogeneity [32]. Shorter and longer sleep durations were positively associated with the risk of sarcopenia [32,41]. Whether other sleep-related traits, like poor sleep quality and insomnia, are associated with sarcopenia deserves exploration.

Diabetes and its complications, and osteoporosis were associated with a high risk of sarcopenia [32,42,43] and these diseases may also be the consequences of sarcopenia as shown above. The bidirectional associations imply mutual influences between muscle and bone systems and between muscle and endocrine systems. Other comorbidities, like heart diseases [32], cognitive impairment [32], respiratory diseases [32], depression [32,44], anorexia [32], and Parkinson's disease [45] were also positively associated with the risk of sarcopenia. However, whether certain associations, like that for heart diseases and cognitive impairment, are causal or linked by confounders, such as ageing, needs to be investigated. Regarding the link between sarcopenia and metabolic

S. Yuan and S.C. Larsson

Table 2

Prevalence of sarcopenia by commonly used definitions after 2010 in two recent systematic reviews.

Definition	Data from Carvalho	lo Nascimento PR [13]		Data from Petermann	Data from Petermann-Rocha F [14]			
	No. of studies	Ν	Prevalence (%)	No. of studies	Ν	Prevalence (%)		
EWGSOP	31	36,811	11 (7–14)	48	200,590	22 (20–25)		
EWGSOP2	4	6624	5 (1–10)	3	5720	10 (2–17)		
AWGS	13	17,070	8 (3–15)	46	27,940	15 (13–17)		
IWGS	5	6993	17 (11–23)	12	11,890	14 (9–18)		
FNIH	5	13,338	15 (5–28)	20	27,864	11 (9–14)		
All above	58	80,836	10 (7–12)	129	274,004	16 (15–17)		

AWGS, Asian Working Group for Sarcopenia; EWGSOP, European Working Group on Sarcopenia in Older People; EWGSOP2, European Working Group on Sarcopenia in Older People 2; FNIH, Foundation for the National Institute of Health; IWGS, International Working Group on Sarcopenia.

Table 3

Prevalence of sarcoper	ia in	patients	with	different	medical	situations.
------------------------	-------	----------	------	-----------	---------	-------------

PMID	First author	Population	Studies	Ν	Prevalence
34399402	Meyer HJ	Patients in critically ill	9	1563	26.3-71.1 %
30389220	Hajibandeh S	Patients with abdominal surgery	20	5324	12.0-56.6 %
28386715	Jones K	Patients with abdominal surgery	24	5267	15-65 %
34078275	Zhang XM	Patients with an intensive care	14	3249	41 %
32131764	Zhang XM	Patients with breast cancer	6	5497	15.9-66.9 %
34337889	Takenaka Y	Patients with cancer receiving immune checkpoint inhibitors	26	2501	21.9-75.0 %
34785325	Tantai X	Patients with cirrhosis	22	6965	37.50 %
34406490	Xie H	Patients with colorectal cancer	19	15,889	12.0-68.2 %
33481108	Trejo-Avila M	Patients with colorectal cancer	44	18,891	37 %
34904651	Feng L	Patients with diabetes	45	12,237	18 %
36235729	Wathanavasin W	Patients with dialysis	41	7576	25.60 %
34989172	Shu X	Patients with dialysis	30	6162	4-68 %
35284466	Xu XT	Patients with diffuse large B-cell lymphoma	12	2324	23.9-55.6 %
30955115	Hua H	Patients with digestive carcinoma surgery	11	2419	11.6-33.0 %
35347823	Ng ZQ	Patients with emergency laparotomy	12	2461	29.50 %
35379520	Park B	Patients with emergency laparotomy	12	6737	34.50 %
35288290	Dakis K	Patients with endovascular aortic aneurysm repair	11	2385	40.30 %
35077542	Chen F	Patients with esophageal cancer	26	4515	14.4-80 %
32193528	Papaconstantinou D	Patients with esophageal cancer	11	1979	14.4-83 %
34249675	Jin SB	Patients with esophageal cancer	11	1485	15.8-60.7 %
29846548	Boshier PR	Patients with esophageal cancer	18	3193	16-75 %
32040700	Wang PY	Patients with esophagectomy	14	2387	36.1-55.3 %
34496449	Li YX	Patients with female cancer	23	3495	46.90 %
29987739	Yang Z	Patients with gastric cancer	13	4262	6.8-57.7 %
34601314	Chen F	Patients with gastric cancer resection	20	7615	6.8-44.8 %
31796090	Su H	Patients with gastrointestinal cancer	70	21,875	2.1-83.3 %
33739153	Wang H	Patients with gastrointestinal oncological surgery	43	16,716	32.3 %
32822372	Pipek LZ	Patients with gastrointestinal surgery	11	4265	6.8-35.9 %
35194194	Sutton EH	Patients with gynecological cancer	27	4286	11-59.2 %
32117787	Hua X	Patients with head and neck cancer	11	2483	6.6-64.6 %
32994071	Findlay M	Patients with head and neck cancer and radiotherapy	7	1059	6.6-64.6 %
32090284	Jia S	Patients with hematopoietic stem cell transplantation	7	1752	35.5-49.0 %.
35876662	Edwards A	Patients with papillomavirus-positive oropharyngeal cancer	9	744	42.90 %
36403578	Zhang JZ	Patients with kidney transplantation	23	2535	26 %
29065187	Kim G	Patients with liver cirrhosis	20	4037	25-70 %
33671958	Wu WT	Patients with lumbar degenerative spine disease	14	1953	24.80 %
31128115	Yang M	Patients with lung cancer (NSCLC)	13	1810	43 %
31128115	Yang M	Patients with lung cancer (SCLC)	13	1810	52 %
32768316	Surov A	Patients with malignant hematological diseases	7	1578	24.6-66.1 %
35578299	Jiang T	Patients with mechanical ventilation	17	3582	43.00 %
35817000	Surov A	Patients with melanoma receiving immunotherapy	6	719	40.20 %
30348603	Deng HY	Patients with non-small cell lung cancer	6	1213	14.0–55.8 %
30266663	Mintziras I	Patients with pancreatic cancer	11	2297	45.40 %
34714876	Takenaka Y	Patients with patients with head and neck cancer	18	3233	13.9–74.7 %
35749415	Zhu Y	Patients with rectal cancer	7	2377	25.6-68.2
32213202	Hu X	Patients with renal cell carcinoma	5	771	25-68 %
36316941	Yuxuan L	Patients with renal cell carcinoma	18	3591	43 %
35794004	Jogiat UM	Patients with resectable esophageal cancer	21	3966	48.10 %
26882087	Shachar SS	Patients with solid tumors	38	7843	11–74 %
31280971	Xia W	Patients with trauma	10	2867	25.0-71.1 %
34479652	Ai Y	Patients with type 2 diabetes	28	16,800	6.3-47.1 %
36151845	Jogiat UM	Patients with unresectable esophageal cancer	5	783	66 %
32268990	Guo Z	Patients with urologic cancer	17	3948	25-68.9 %
30871883	Hu X	Patients with urothelial carcinoma	12	2075	20-75 %

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

S. Yuan and S.C. Larsson

Metabolism xxx (xxxx) xxx

333763 Mp 2.0 Emergency lepsebury 12 241 33-deg monitally Oke 33 (1) 14-4 333763 Mun G Comment survey 12 231 33-deg monitally Oke 33 (1) 16-7 (6) 3367153 Mun G Comment survey 12 233 33-deg monitally Oke 33 (1) 16-7 (6) 3367153 Mun G Comment survey 12 237 33-deg monitally Oke 33 (1) 16-7 (6) 3367153 Mun G Comment survey 12 237 33-deg monitally Oke 33 (1) 16-7 (6) 338100 Mun G Comment survey 12 237 75 <td< th=""><th>PMID</th><th>First author</th><th>Population</th><th>Studies</th><th>N</th><th>Indicator</th><th>Association</th><th></th></td<>	PMID	First author	Population	Studies	N	Indicator	Association	
553.723 Ng 20 Emergency (apactory) 12 246 1 - year modelly 0.0 3.48 (2.16 - 6.5)	35347823	Ng ZQ	Emergency laparotomy	12	2461	30-day mortality OR	3.50 (2.54-4.81)	
Starting L Startin L Startin L Starting	35347823	Ng ZQ	Emergency laparotomy	12	2461	1-year mortality OR	3.49 (2.16-5.65)	
956515 that H Digestive carcinoma surgery 11 2419 30-day incidally RR 3.36 (180-7.60) 93801130 Daw MJ Lung concer 10 2264 How may the price of the pr	29987364	Sun G	Nonmetastatic colorectal cancer	12	5337	Mortality OR	3.45 (1.69-7.02)	
1919557 Built Diff Ling cancer 15 2521 Morally HR 313 (266-176) 25375520 Park E Emergency learner 10 266 (162-460) 25375520 Yang MA Emergency learner 11 2736	30955115	Hua H	Digestive carcinoma surgery	11	2419	30-day mortality RR	3.36 (1.60-7.60)	
13280571 Xia W Tauma 10 2867 1-year forstally RR 3.11 (124-4.50) 13280571 Yuang Carlos anone methody 9 2167 Poor constall service RR 3.11 (124-4.50) 13280571 Yuang Carlos anone methody 9 2167 Poor constall service RR 2.76 (2.65-3.7) 13280571 Marg TM Bargency Igantomy 10 3767 3767 3767 13739153 Marg TM Bargency Igantomy 11 3767 3767 1176-10 210 (12-3.10) 111-1 13739153 Marg TM Red anone 7 2277 Poor constall service IRR 2.21 (12-3.60) 111-1 13739153 Marg TM Red anone 7 2270 Poor constall service IRR 2.21 (12-3.60) 111-1 13739153 Marg TM Red anone 7 2270 120 (12-3.80) 111-1 13739153 Marg TM Red anone 7 2270 (12-3.80) 111-1 111-1 13739153 Marg TM Red anone 7 2270 (12-3.80) 111-1 111-1 111-1 111-1 111-1 111-1	31519557	Buentzel J	Lung cancer	15	2521	Mortality HR	3.13 (2.06-4.76)	
Statistics Kanogenth Y Ling clancer 10 2640 Peor overflit survival OR 2.07 (245-385) 9714570 The survival FR Emergy projection (2000) 2.07 (245-385) Image monty QR 2.00 (245-385) 9714570 The survival FR Emergy projection (2000) 2.00 (245-385) Image monty QR 2.00 (245-385) 9715575 The survival FR Emergy projection (2000) 2.00 (245-385) Image monty QR 2.20 (165-385) 9715575 The survival FR Emergy projection (2000) 2.00 (245-385) Image monty QR 2.21 (155-385) 9715757 Strange MA Controls (2000) 2.00 (2400) 2.00 (2400) 2.00 (2400) 2.00 (2400) 9715757 Strange MA An Infensive care in tampionization (1400) 2.20 (145-285) Image montal (1400) 2.00 (2400) Image montal (1400) Image montal (1400) Image montal (1400) 2.00 (1400) Image montal (1400) <td>31280971</td> <td>Xia W</td> <td>Trauma</td> <td>10</td> <td>2867</td> <td>1-year mortality RR</td> <td>3.11 (1.94-4.96)</td> <td></td>	31280971	Xia W	Trauma	10	2867	1-year mortality RR	3.11 (1.94-4.96)	
35379530 Park E Emergency laportomy 12 6737 Types montailly OR 2.201 (26-5.80) 35379530 Margin Link Emergency laportomy 13 3755 Margin Link 2.201 (26-5.80) 35775535 Wing TR Emergency laportomy 13 3755 30-day mortailly rate OR 2.201 (26-5.80) 35775535 Wing TR Emergency laportomy 13 3755 30-day mortailly rate OR 2.201 (26-5.80) 35775535 Wing TR Controlleration and marked and mortail and the control a	33841929	Kawaguchi Y	Lung cancer	10	2643	Poor overall survival OR	3 07 (2 45-3 85)	·
34398302 Mayer HJ Colitality HI 278 (20.63-77) 9474676 Teambark Y Head neck cancer 16 353 Parcental aurival HR 22.62 (16.63-37) 93730135 Mayer HJ Genetypery laparotationy Genetal aurival HR 22.01 (16.5-46) 1 93730135 Junia XM Carthols 77 Parcental aurival HR 22.01 (15.5-46) 9474057 Tamina XM Carthols 20 13.12 (15.1-26) 1 94705357 Junia XM Carthols 21 62.97 Monthly HR 22.01 (15.2-63) 1 94705357 Junia XM Carthols Carthols 21 62.97 Monthly HR 22.61 (16.2-26) 1 94710571 France overall aurival RR 22.81 (16.2-27) 1 </td <td>35379520</td> <td>Park B</td> <td>Emergency Japarotomy</td> <td>12</td> <td>6737</td> <td>1-vear mortality OR</td> <td>2 80 (1 50-5 60)</td> <td></td>	35379520	Park B	Emergency Japarotomy	12	6737	1-vear mortality OR	2 80 (1 50-5 60)	
Series Head and manual y Head and manual y Head and manual y Series Poor owned mundal HR 2.00 (19-92.21) ST3115 Stress Manual Y Stress St	24200402	Moyor HI	Critically ill	0	1562	Mortality UP	2.00 (1.00 0.00)	
212:02:00 Ving TR Emerging Lipsophic Diagram 11 3726 20-da monality On 2.22 (16) 3-201 379153 Wing TR Good and monality OR 2.24 (16) 3-201	24714076	Takapaka V	Head and neak appear	10	1000	Deer everall everywel UD	2.70 (2.05-3.75)	
323233 Utage 1, How the three percent structure of the tempercent structure of tempercen	26752055	Vara TD		10	3233		2.30 (1.93-3.21)	
32 34 34 34 The Later or result approximation and the second	30/02800	Yang IR	Emergency laparotomy	11	3795	30-day mortality OR	2.42 (1.93-3.05)	
9274845 Zhu Y Rectal cancer 7 2277 Photo neural survival HR 2.37 (13-4.89) 9278757 Zhang MM All intersive care 14 2349 Photo neural survival HR 2.37 (13-4.89) 92805024 Jia S Hemitopides tam cell transplantation 7 1722 Photo neural survival HR 2.21 (13-2.80) Image and transplantation 92805024 Jia S Hemitopides tam cell transplantation 7 1722 Photo neural survival HR 2.16 (16-2.27) 92817757 Hang M Connary stery disease 10 3707 Mottally OR 2.11 (17-2.67) 92872893 Xue C Sagadi meta cancer 11 2.48 Mottally OR 2.11 (17-2.67) 9287297 Findag M Head and neck cancer 10 2.28 Mottally OR 2.11 (17-2.67) 9287298 Findag M Head and neck cancer 10 2.28 Mottally OR 2.11 (14-2.10) Image M 9287297 Findag MA Head and neck cancer 10 2.18 Por overall survival HR 2.00 (14.2.25) I	33739153	Wang H	Gastrointestinal oncological surgery	43	16716	30-day mortality rate OR	2.38 (1.56-3.63)	
34 #8503 Tantal X, M. Cinheals 22 6963 Metally JR 2.3 (201-2.63) Image: Control Science Control Scienc	35749415	Zhu Y	Rectal cancer	7	2377	Poor overall survival HR	2.37 (1.13-4.98)	
3407827 Zhang XM An Intensive care 14 3249 Mortally CR 2.28 (183-2.83) 3007824 July Helmachonic 17 1782 Procerveral survival CR 227 (133-2.83) 3007824 July Helmachonic 1782 Procerveral survival CR 221 (133-2.83) 3007824 July Helmachonic 1782 Procerveral survival CR 221 (133-2.83) 3007824 July Helmachonic 1782 Procerveral survival CR 221 (137-3.83) 3007824 July Helmachonic 1782 Procerveral survival CR 211 (176-2.79) 1111 2863 Procerveral survival HR 2.11 (176-2.70)	34785325	Tantai X	Cirrhosis	22	6965	Mortality HR	2.30 (2.01-2.63)	·
32805024 Hematopoints stem cell transplantation 7 1752 Poor overall survival RR 227 (133-365) 3280504 Vang M Coronary attry disease 10 37777 Mortally HR 215 (108-524) 3422180 Yung M Coronary attry disease 10 37777 Mortally HR 215 (108-527) 34211787 Hun X Head and neck cancer 11 2483 Mortally risk RR 2.15 (108-527) 34211787 Hun X Head and neck cancer 11 2483 Poor overall survial RR 2.14 (165-2.67) 342542688 Yung L Belging intract cancer 10 3238 Poor overall survial RR 2.12 (165-2.67) 325842688 Yung L Belging intract cancer 10 3238 Poor overall survial RR 2.12 (165-2.67) 3258204 Hundighe Cancer 10 3238 Poor overall survial RR 2.16 (165-2.67) 3252204 Hundighe Cancer 10 3238 Poor overall survial RR 12 (177-5.20) 3222207 Hundighe Cancer 10 3238 Poor overall s	34078275	Zhang XM	An intensive care	14	3249	Mortality OR	2.28 (1.83-2.83)	·
1128115 Yang M Lung cancer 13 1610 Poor overall survial HR 223 (1.68-2.94) 21311727 Hua X Head and next cancer 11 20.343 Dord ymortalli WR 2.15 (1.58-2.76) 21311727 Hua X Head and next cancer 11 20.343 Dord ymortalli Wrat R 2.15 (1.58-2.76) 21311727 Hua X Mechanical verificities 17 2582 Mortally OR 2.13 (1.70-2.67) 21311727 Hua X Mechanical verificities 17 2582 Mortally OR 2.13 (1.70-2.67) 213220207 Jones K Mechanical verificities 17 3582 Mortally OR 2.13 (1.70-2.67) 2220070 Jones K Abdominal surgery 24 25207 30-day mortally KR 2.06 (1.02-4.17) 2220070 Wong A.on X Mada and next cancer 10 2.118 Poor overall survial HR 2.06 (1.02-4.17) 2220070 Wong A.on X Mada and next cancer 10 2.121 Poor overall survial HR 1.00 (1.52.2.37) 2220071 Wong A.on X Mada and next cancer 10 2.121 Poor overall survial HR 1.	32090284	Jia S	Hematopoietic stem cell transplantation	7	1752	Poor overall survival OR	2.27 (1.33-3.85)	
Hajlbandeh S. Abdöminal surgery 20 5324 30-day motally RR 2.15 (15-10.6) 211772 Hus M. Head an neck cancer 10 2433 Peor ownall survival RR 2.15 (15-10.6) 257775 Hus M. Head an neck cancer 10 2443 Peor ownall survival RR 2.15 (15-2.67) 2587289 Jang T. Mechnical venillation 17 2582 Mortelly OR 2.13 (17.72 e) 2587289 Jang T. Mechnical venillation 17 2582 Deor ovenall survival RR 2.12 (14-5.10) 2587289 Jang M. Blary tract cancer 16 2261 Deor ovenall survival RR 2.12 (14-5.10) 2587289 Jang M. Hagibandeh S. Abdominal surgery 20 5334 D-year morallsurvival RR 2.01 (14-2.10) 2587289 Jang M. Hajbandeh S. Abdominal surgery 20 5334 D-year morallsurvival RR 1.92 (15.5-2.53) 2587289 Hajbandeh S. Abdominal surgery 20 5334 1-year morallsurvival RR 1.92 (15.5-2.51) 2587289 Hajbandeh S. Abdominal survival RR 1.97 (15.2-2.51) Hajba	31128115	Yang M	Lung cancer	13	1810	Poor overall survival HR	2.23 (1.68-2.94)	
3421280 Xue Q Coronary attry desage 10 3707 Mortally HR 215 (0.89-52) 3212787 Hu X Head and neck cancer 11 2438 Poor overall survial RR 214 (160-2.67) 3212787 Hu K Sepais 17 2368 Mortally risk RR 214 (160-2.67) 3221787 Hu K Head and neck cancer 11 2438 Poor overall survial RR 212 (162-5.70) 32842680 Wing L Billy Hy Inct cancer 16 3231 Poor overall survial RR 212 (162-5.70) 3284261 Jones K Abdornial surgery 20 5267 30-day mortally RR 2207 (147-5.20) 328207 H Jones K Abdornial surgery 20 5324 1-year nortally RR 127 (142-5.25) 32220702 Wong A Head and neck cancer 10 2317 Poor overall survial RR 187 (145-2.69) 32220703 Billy Boor Nortally RR 127 (145-2.60) Heid (152-2.67) Heid (152-2.67) 32217051 Billy Boor Nortally RR 127 (145-2.60) Heid (152-2.67) Heid (152-2.67) 32217051 Billy Boor Nortally RR 127 (145-2.60) Heid (152-2.67) Heid (152-2.67)	30389220	Haiibandeh S	Abdominal surgery	20	5324	30-day mortality RR	2.15 (1.51-3.05)	·
1211727 Hua X Head and next center 11 2483 Poor Overall survival HR 2.15 (166-2.27) 557259 Jang T Mochanical winliction 17 3582 Mortality risk KR 2.14 (160-2.87) 557259 Jang T Mochanical winliction 17 3582 Mortality risk KR 2.14 (160-2.87) 557259 Jang T Mochanical winliction 17 3582 Mortality risk KR 2.14 (160-2.87) 5572599 Jones K Abdominal surgery 24 5267 30-day mortality RR 2.06 (102-4.17) 52258990 Guo Z Hold and neck cancer 10 2.181 Poor overall survival HR 2.06 (142-2.95) 52258905 Guo Z Hold and neck cancer 12 2.334 Poor overall survival HR 1.90 (152-2.37) 52258905 Guo Z Driftue large B-cell symptoma 12 2.334 Poor overall survival HR 1.81 (140-2.39) 5235484 Rubor NB Choice kida cancer 2 317 Mortality risk KR 1.83 (157-2.14) 5336416 Rubor NB Choice kida cancer 2 33 416 1.92 (128-2.37)	34521369	Xue Q	Coronary artery disease	10	3707	Mortality HR	2 15 (0 89-5 22)	
56655326 Liu W Sepsis 10 2366 Mortality OR 2.13 (160-247) 5572269 Jung T Bilary tract cancer 18 3261 Poor overall survival HR 2.12 (146-3.10) 5557269 Jung T Bilary tract cancer 18 3261 Poor overall survival HR 2.01 (147-23) 3258590 Find A Hade and neck cancer 10 2184 Poor overall survival HR 2.06 (144-245) 3258200 Guo Z Uvologic canoer 10 2184 Poor overall survival HR 186 (146-2.36) 3258200 Kurd A Adad and neck cancer 10 2184 Poor overall survival HR 186 (146-2.36) 3258210 Survin A Maigrant henaloogrand diseases 12 2075 Poor overall survival HR 187 (135-2.45) 3258310 Survin A Cobrecta cancer 44 1881 Poor overall survival HR 188 (147-2.37) 3263105 Frain KR Trip KR Trip KR 188 (137-2.41) Hutter 32631105 Conroci kong disease 8 2117 Mortality KR 188 (137-2.41) 32631105 Trip KR	32117787	Hua X	Head and neck cancer	11	2483	Poor overall survival HR	2 15 (1 66-2 79)	
3257289 Liang T Machason 17 2352 Montaining (Chr. 2.13 (177-267) 3254268 Yang L Billary (Tat Cancer and radichterapy 7 1059 Poor overall survival HR 2.12 (148-3.10) 3254268 Yang K Addominal surgery 24 3264 Poor overall survival HR 2.07 (147-287) 3258207 Hinding K Addominal surgery 20 3344 Poor overall survival HR 2.06 (124-4.37) 3258208 Guo Z Urologic cancer 10 3544 Poor overall survival HR 19 (154-2.37) 3258208 Survo A Malignant hematological diseases 7 177 78 Poor overall survival HR 19 (152.2.37) 3258208 Highandeh S Adominal surger 20 1234 Poor overall survival HR 18 (152.2.43) 3258208 Highandeh S Adominal surger 16 (152.2.37) Highandeh S Adominal surger 18 (140.2.37) 3258208 Highandeh S Adominal surger 18 (140.2.37) 18 (140.2.37) 14 (130-2.2.8) Highandeh S 32631084 Nucun L Real call carainoma 18 (356) 20 (163	25605526		Pennin	10	2405	Montality riak DD	2.13 (1.00 2.73)	
3231232 Junit 1 Milling M Milling M 16 3282 Point of M 1212116-510 32390707 Finding M Head and neck cancer and radiotherapy 7 1059 Poor overall survival HR 20071147-220 1 32390707 Finding M Head and neck cancer 10 2181 Poor overall survival HR 206 (102-417) 32390707 Finding M Head and neck cancer 10 2181 Poor overall survival HR 180 (184-239) 32200707 Finding M Head and neck cancer 10 2181 Poor overall survival HR 180 (184-239) 32201707 Profine Sing Pool (1968ases 7 1757 Profine overall survival HR 180 (18-237) 323118 Toincik Kingy Giasese 8 2117 Mortality fisk 181 (157-16) 1 323118 Toincik Kingy Giasese 8 2117 Mortality fisk 181 (157-16) 1 1 323118 Toincik Kingy Giasese 8 2117 Mortality fisk 181 (157-16) 1 1 1 1	350055550	Liu VV	Mashanianlumatilation	10	2590	Mantality ISK KK	2.14 (1.00-2.07)	
2522.259 Tright, Market Scholer 16 20.00	355/8299	Jiang I	Mechanical ventilation	17	3582	Mortality OR	2.13(1.70-2.67)	
224940/11 Endag, M Head and neck cancer 10.9 Poor overall survival HR 21.06 (14-2.92) 225000 Uk. Z Vickogic cancer 17 33.8 Poor overall survival HR 1.06 (14-2.92) 225000 Uk. Z Vickogic cancer 10 2181 Poor overall survival HR 1.06 (14-2.93) 225000 Uk. Z Mickogic and neck cancer 10 2181 Poor overall survival HR 1.96 (142-2.93) 2250800 Surv A Malignant hematological diseases 7 1578 Poor overall survival HR 1.97 (153-253) 23637681 Yu.X Concretal cancinoma 12 2207 Poor overall survival HR 1.87 (143-2.45) 38671683 Yu.X Urobelial cancinoma 12 2207 Poor overall survival HR 1.87 (143-2.45) 38671681 Yu.X Epifelial cancinoma 12 217 Poor overall survival HR 1.87 (143-2.45) 3222170 Vickianavasin Dialysis 41 7576 Morally Irikk CR 1.83 (140-2.37) 32221370 Wichanavasin	35542968	Yang L	Billary tract cancer	18	3261	Poor overall survival HR	2.12 (1.46-3.10)	
Bases Fit Jones K Abdominal surgery 24 5267 30 - day mortally FR 206 (14.2-4.17) 22283890 Qu A Abdominal surgery 10 238 H Poor overall survival FR 1.97 (15.3-2.53) 3238220 Hajlbandeh S Abdominal surgery 20 5324 - year mortally FR 1.97 (15.3-2.53) 3258466 Xu XT Diffuse large B-cell lymphoma 12 2344 Poor overall survival FR 1.99 (15.2-2.37) 3258466 Xu XT Diffuse large B-cell surphoma 12 2344 Poor overall survival FR 1.87 (13.5-2.59) 32613664 Xu XT Othelial carcinoma 14 2018 Poor overall survival FR 1.83 (14.0-2.30) 32613647 Yu Ania M Othelial carcinoma 18 3511 Poor overall survival FR 1.83 (14.0-2.30) 32613729 Watahia M Renal cell carcinoma 18 3511 Poor overall survival FR 1.83 (14.0-2.30) 3221322 Yu Ania M Renal cell carcinoma 10 1.22 (13.2-2.0)	32994071	Findlay M	Head and neck cancer and radiotherapy	1	1059	Poor overall survival HR	2.07 (1.47-2.92)	+
3226890 Guo Z Urologic cancer 17 3948 Poor overall survia IR 2.06 (1.44-2.95) 322007 Wong An Analyment surgery 10 2.18 Poor overall survia IR 1.98 (1.64-2.95) 3278310 Bionov An Analyment surgery 10 2.18 Poor overall survia IR 1.98 (1.64-2.95) 3278314 Rux UAT Diffuse large B-oell ymphoma 12 2.24 Poor overall survia IR 1.83 (1.35-2.59) 3434164 Ribeiro HS Chronic Kidney disease 8 2.117 Mortality IRR 1.83 (1.45-2.41) 3434168 Tie/o Linking disease 12 2.057 Poor overall survia IRR 1.83 (1.45-2.45) 3434180 Tripe-Avila M Colorectal cancer 44 18891 Poor overall survia IRR 1.83 (1.40-2.30) 3434180 Tripe-Avila M Colorectal cancer 2.3 3495 Poor overall survia IRR 1.83 (1.40-2.30) 34499 Diaviss 30 162 Mortality Irsk IR 1.82 (1.30-2.30) 34499 Diaviss 30 162 Sor overall survia IRR 1.76 (1.35-2.31) 3446940 L'Y	28386715	Jones K	Abdominal surgery	24	5267	30-day mortality RR	2.06 (1.02-4.17)	
2222072 Wong A Head and neck cancer 10 2181 Poor overall survival HR 1.98 (164-2.39) 22788316 Surviv A Malignant hematological diseases 7 1578 Poor overall survival HR 1.84 (130-2.30) 22788316 Surviv A Malignant hematological diseases 7 1578 Poor overall survival HR 1.84 (132-2.30) 22788316 Huk X Urotheila carcinoma 12 2075 Poor overall survival HR 1.87 (143-2.45) 3087168 Hux X Urotheila carcinoma 18 351 Poor overall survival HR 1.83 (147-2.3) 3087189 Hux X Dialysis 41 756 Morality risk OR 1.83 (147-2.3) 30871894 Yuxuan L Renal cell carcinoma 18 351 Poor overall survival HR 1.82 (147-2.3) 30871897 Yuxuan L Renal cell carcinoma 5 771 Poor overall survival HR 1.72 (138-2.3) 3087307 Li K Cancer receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.77 (148-2.0) 3087307 Li K Cancer receiving immune checkpoint inhibitors 19	32268990	Guo Z	Urologic cancer	17	3948	Poor overall survival HR	2.06 (1.44-2.95)	·
Majlbändeh S Addominal surgery 20 5324 1 - year mortality RR 1.97 (1.53-2.53) 35284364 Rusvin A Diffuse large B-cell lymphoma 12 2334 Poor overall survival HR 1.90 (1.52-2.57) 35284364 Ruskin-HS Diffuse large B-cell lymphoma 12 2334 Poor overall survival HR 1.80 (1.52-2.57) 353614 Ruskin-HS Diffuse large B-cell lymphoma 12 2334 Poor overall survival HR 1.83 (1.67-2.40) 3536110 Trat-Availa M Doarosetal technoma 12 2384 Poor overall survival HR 1.83 (1.67-2.40) 353611041 Yuxuan L Rend cell carcinoma 18 3591 Poor overall survival HR 1.83 (1.47-2.31) 35221737 McSharry V Epithelial ovarian cancer 6 1226 Poor overall survival HR 1.80 (1.00-3.20) 3221370 Hux Renal call carcinoma 5 7771 Poor overall survival HR 1.78 (1.35-2.31)	32220072	Wong A	Head and neck cancer	10	2181	Poor overall survival HR	1.98 (1.64-2.39)	
32768316 Suiov A Malgnant hemätological diseases 7 1578 Poor overall survival HR 1.94 (1.30–2.90) 3543046 Ku XT Dirthiela large Beellymphome 12 2324 Poor overall survival HR 1.80 (1.35–2.80) 3543046 Ku XT Dirthiela large Beellymphome 12 2324 Poor overall survival HR 1.87 (1.35–2.80) 3543054 Ku XT Dirthiela large Beellymphome 12 2324 Poor overall survival HR 1.87 (1.35–2.80) 35330540 Vuxuan L Renal cell carcinoma 14 7578 Poor overall survival HR 1.83 (1.40–2.30) 35310541 Vuxuan L Renal cell carcinoma 18 3591 Poor overall survival HR 1.82 (1.38–2.30) 3416941 L/X Femal cell carcinoma 5 777 Poor overall survival HR 1.73 (1.38–2.30) 34469440 L/X Femal cell carcinoma 5 777 Poor overall survival HR 1.73 (1.38–2.30) 34439444 L/X Renal cell carcinoma 5 777 Poor overall survival HR 1.73 (1.38–2.30) 344495704 L/S Cancers meaviving immune checkpoint inhibitors	30389220	Haiibandeh S	Abdominal surgery	20	5324	1-vear mortality RR	1.97 (1.53-2.53)	
15284466 Xu XT Diffuse large B-cell lymphona 12 2224 Poor overall survival HR 1.800 (152, 2.37) 1528456 Ribbior MS Urothelial carcinoma 12 2007 Mortally HR 1.87 (143, 2.45) 1528456 Ribbior MS Urothelial carcinoma 12 2007 Mortally HR 1.87 (143, 2.45) 15284567 Wathanaxeain W Dialysis 1.000 (152, 2.37) 1.000 (152, 2.37) 15284567 Wathanaxeain W Dialysis 1.000 (152, 2.37) 1.000 (152, 2.37) 15284567 Wathanaxeain W Dialysis 1.000 (152, 2.37) 1.000 (152, 2.37) 1528757 Wathanaxeain W Dialysis 1.000 (152, 2.37) 1.000 (152, 2.37) 1528757 U.X Renale cancer 2.33456 Poor overall survival HR 1.80 (10-3.20) 15281767 U.S Cancer receiving immune checkpoint inhibitors 19 1733 Mortally HR 1.73 (1.45-2.19) 1411767 1.900 (152, 2.37) 1.900 (152, 2.37) 1.900 (152, 2.37) 1.900 (152, 2.37) 152813770 Cancer receiving immune chec	32768316	Surov A	Malignant hematological diseases	7	1578	Poor overall survival HR	1.94 (1.30-2.90)	·
35330544 Ribeiro HS Chronic kidney disease 8 2117 Mortality HR 187 (138-2.59) 3530544 Ribeiro HS Colorectal cancer 44 1889 1143-2.45 143-2.45 33381108 Trojo-Avia M Colorectal cancer 44 1889 1143-2.45 143-2.45 33381108 Trojo-Avia M Colorectal cancer 44 1889 114111 123 (147-2.37) 33381108 Trojo-Avia M Renal cell carcinoma 18 3591 Poor overall survival HR 123 (147-2.37) 33397307 Li HL Renal cell carcinoma 5 123 (147-2.37) 140 (130-2.00) 33397307 Li HL Cancer receiving immune checkpoint inhibitors 19 171 Poor overall survival HR 173 (148-2.07) 31563796 Li J Urologic tumors 16 2264 Poor overall survival HR 173 (148-2.01) 31563796 Li J Urologic tumors 16 2264 Poor overall survival HR 173 (148-2.01) 31563796 Li J Urologic tumors 16 2264 Poor overall survival HR 173 (148-2.01) 31565776 L	35284466	XII XT	Diffuse large B-cell lymphoma	12	2324	Poor overall survival HR	1 90 (1 52 2 37)	
3037183 Hu X Urothelial carcinoma 12 2075 Poor overall survival HR 137 (145-246) 303718108 Tipo Avila M Dialysis 41 7576 Mortally risk OR 133 (147-23) 303213273 Wathanavasin W Dialysis 30 6162 Forevarial survival HR 133 (147-23) 30351991 Yuxuan L Renal cell carcinoma 18 3591 Poor overall survival HR 138 (147-23) 34369172 Shu X Dialysis 30 6162 5-year survival OR 180 (10-3-20) 34496449 L'X Female cancer 23 3495 Poor overall survival HR 177 (132-2.30) 34496449 L'X Female cell carcinoma 5 771 Poor overall survival HR 177 (142-2.01) 33873071 L'I AL Cancer 6 1226 Poor overall survival HR 177 (147-2.02) 33873073 L'I AL Cancer 6 547 Mortality HR 177 (125-2.32) 3460314 Chen F Gastric cancer reserving immune checkpoint inhibitors 9 740 Poor overall survival rule HR 177 (145-19)	35/305//	Ribeiro HS	Chronic kidney disease	8	2117	Mortality HR	1.87 (1.35-2.50)	·
3338 1109 Tup-Anila M. Coloractic clustering 44 21891 Paper overall survival HR 1.83 (157-214) 3328 1109 Tup-Anila M. Renal cell carcinoma 18 3591 Phor overall survival HR 1.83 (147-2.37) 38319307 Withmarvasin W. Renal cell carcinoma 18 3591 Poor overall survival HR 1.83 (147-2.37) 38211941 Yuxuan L. Renal cell carcinoma 6 1226 S-year survival OR 1.80 (1.00-3.20) 32221377 McSharry V. Epithelial ovarian cancer 6 1226 S-year survival HR 1.73 (1.38-2.30) 3221302 Hu X. Renal cell carcinoma 5 771 Poor overall survival HR 1.73 (1.38-2.30) 32213704 Li S. Cancer receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.73 (1.38-2.30) 32187612 Li W. Cancer receiving immune checkpoint inhibitors 20 4037 Mortality HR 1.77 (1.38-2.31) +++ 32187612 Kima X. Renal cancer 6 5427 Mortality HR 1.77 (1.38-2.31) +++ 32187612 None sell cancer	20071002		Urotholial carcinoma	12	2075	Poor overall curvival UP	1.07 (1.00 2.00)	
3283 1729 Tright Antin Ming Dialogistic data factor 41 770 Producting as une number of the state and the number of the state and the number of the state and the s	224011003	Train Avila M		12	2075	Poor overall survival HD	1.07 (1.43-2.43)	
902.321.20 Wathalawashi W Diallysis 41 97.0 Mortality first OK 1.63 (140-2.33) 902.321.20 Wathalawashi W Diallysis 6 3361 Provide and Status 1.63 (140-2.33) 902.321.21 Bit Mit Status Constraint 6 6 Status 1.63 (140-2.33) 902.321.22 Hu X Renat cell carcinoma 5 77.1 Poor overail survival HR 1.76 (135-2.31) 922.1302.20 Hu X Renat cell carcinoma 5 77.1 Poor overail survival HR 1.76 (135-2.31) 9397307 Li Hu Cancer 81 127.31 Mortality HR 1.74 (1.46-2.07) 94513704 Li S Cancers receiving immune checkpoint inhibitors 19 176.3 Poor overail survival HR 1.73 (1.43-2.10) 93056187 Kin G Liver cirrhosis 20 4037 Mortality HR 1.74 (1.45-2.31) Her 931764 Li S Gastric cancer receiving immune checkpoint inhibitors 9 716 Poor overail survival RR 1.71 (1.35-2.01) Her	33401100	Methoda and M	Distusia	44	10091	Mantality sials OD	1.03 (1.37-2.14)	
95:10=94 TuXuan L Nendal Cell Carcinoma 18 Sep 1 Poor overall survival HR 1.82 (1:36-2:37) 94:89172 Nu X Epithelial ovarian cancer 6 122 5-years survival OR 1.80 (1:00-3:20) 92:221737 McSharry V Epithelial ovarian cancer 6 122 5-years survival OR 1.80 (1:00-3:20) 93:13070 Li X Cancer seceining immune checkpoint inhibitors 5 737 Mortally HR 1.73 (1:46-2:07) 93:15776 Li J Urologic tumors 16 2.64 Poor overall survival HR 1.73 (1:46-2:01) 93:169776 Li J Urologic tumors 16 2.64 Poor overall survival HR 1.73 (1:46-2:01) 93:169776 Li J Urologic tumors 6 5497 Mortally HR 1.77 (1:25-2:33) 93:169776 Li J Urologic tumors 6 1226 S-years survival RR 1.71 (1:35-1.91) 93:168797 Deng HY Solid cancer resection 20 7615 Poor overall survival RR 1.77 (1:39-2.10) 93:221737 M	30235729	watnanavasin w	Dialysis	41	/5/6	Mortality risk OR	1.83 (1.40-2.39)	
34989172 Shu X Diajvisis 30 6162 Mortality mix HR 1.82 (1.38-2.39) 34489449 Li YX Female cancer 23 3499 Poor overail survival HR 1.78 (1.38-2.30) 34489449 Li YX Female cancer 23 3499 Poor overail survival HR 1.77 (1.38-2.30) 3387307 Li HL Cancer receiving immune checkpoint inhibitors 19 1731 Moortality HR 1.74 (1.46-2.07) 31867976 Li J Urologic tumors 16 2264 Poor overail survival HR 1.73 (1.48-2.19) 31867976 Li J Urologic tumors 20 4064 Mortality HR 1.74 (1.45-2.07) 31867976 Li J Urologic tumors 20 4064 Poor overail survival HR 1.77 (1.53-1.91) 3468114 Cheng XM Betacancer 8 3193 Poor 1-year overail survival HR 1.77 (1.53-1.91) 3468377 Weig XM Esophageal cancer 18 3193 Poor 1-year overail survival RR 1.70 (1.08-2.10) 32221737 McShary V Esophageal cancer 18 3193 Poor overail survival RR 1.70 (1.45-1	36316941	Yuxuan L	Renal cell carcinoma	18	3591	Poor overall survival HR	1.83 (1.41-2.37)	·
2221737 McShary V Epithelial ovarian cancer 6 1226 5-year survival OR 1.80 (1.00-3.20) 221302 Hu X Renal cell carcinoma 5 771 Poor overall survival HR 1.76 (1.35-2.31) 33997307 Li L Cancers receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.73 (1.46-2.07) 34513744 Li S Cancers receiving immune checkpoint inhibitors 16 2264 Poor overall survival HR 1.73 (1.46-2.07) 34605174 Li S Cancer receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.72 (1.27-2.32) 3460314 Chen F Gastric cancer receiving immune checkpoint inhibitors 9 740 Poor 1-year overal survival RR 1.71 (1.35-1.91) +++ 3460314 Chen F Gastric cancer 6 5497 Mortality HR 1.70 (0.80-3.50) ++ 3221737 McShary V Epithelial ovarian cancer 13 4262 Poor overall survival RR 1.71 (1.35-1.91) ++ 34166897 Deag Shier PR Esophageal cancer 13 4262 Poor overall survival RR 1.66 (1.62-4.183) <td>34989172</td> <td>Shu X</td> <td>Dialysis</td> <td>30</td> <td>6162</td> <td>Mortality risk HR</td> <td>1.82 (1.38-2.39)</td> <td>→</td>	34989172	Shu X	Dialysis	30	6162	Mortality risk HR	1.82 (1.38-2.39)	→
94486449 Li YX Female cancer 23 3495 Poor overall survival HR 1.78 (1.38–2.30) 3397307 Li HL Cancer Stronger 171 Mortality HR 1.74 (1.46–2.07) 3397307 Li HL Cancers receiving immune checkpoint inhibitors 16 12731 Mortality HR 1.73 (1.48–2.01) 31657797 Li J Urologic tumors 16 2264 Poor overall survival HR 1.73 (1.48–2.01) 31657797 Li J Urologic tumors 6 24037 Mortality HR 1.71 (1.25–2.33) 31657976 Li J Gastric cancer resection 6 7615 Poor overall survival RR 1.71 (1.25–2.33) 3221370 McSharry V Solid cancers receiving immune checkpoint inhibitors 8 720 Poor overall survival RR 1.71 (1.39–2.10) 34165647 Feng P Solid cancers receiving immune checkpoint inhibitors 9 720 Poor overall survival RR 1.70 (1.45–1.83) 34165647 Feng P Esphaged cancer 13 2462 Poor overall survival RR 1.70 (1.45–1.83) 3581700 Surov A Melanoma receiving immuncherapy 6	32221737	McSharry V	Epithelial ovarian cancer	6	1226	5-year survival OR	1.80 (1.00-3.20)	· · · · · · · · · · · · · · · · · · ·
1221202 Hu X Renal cell carcinoma 5 771 Poor overall survival HR 1.76 (1.35-2.31) 33997307 Li K Cancers receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.73 (1.36-2.19) 34513704 Li S Cancers receiving immune checkpoint inhibitors 16 2264 Poor overall survival HR 1.73 (1.36-2.19) 31567976 Li ver cirrhosis 20 4037 Mortality HR 1.71 (1.25-2.32)	34496449	Li YX	Female cancer	23	3495	Poor overall survival HR	1.78 (1.38-2.30)	
33997307 Li HL Cancer receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1,74 (1,46-2.07) 4513704 Li S Cancer receiving immune checkpoint inhibitors 16 Poor overall survival HR 1,73 (1,48-2.01) 92065187 Kim G Live cirbosis 20 4037 Mortality HR 1,73 (1,48-2.01) 9213764 Zhang XM Breast cancer 6 5497 Mortality HR 1,71 (1,25-2.33) 94061314 Chen F Gastric cancer resection 20 7615 Poor 1-year overall survival RR 1,71 (1,39-2.10) 94665867 Deng HY Solid cancer 13 4262 Poor roverall survival RR 1,70 (1,33-2.17) 92846548 Boshier PR Esophageal cancer 13 4262 Poor overall survival HR 1,70 (1,35-2.17) 93847354 Yang Z Gastric cancer 13 4262 Poor overall survival HR 1,61 (1,12-2.52) 93847354 Yang Z Gastric cancer 13 4262 Poor overall survival HR 1,61 (1,12-2.48) 93847354 Yang Z Gastric cancer 13 4267 Poor overall survival	32213202	Hu X	Renal cell carcinoma	5	771	Poor overall survival HR	1.76 (1.35-2.31)	→ → →
34613704 Li S Cancers receiving immune checkpoint inhibitors 19 1763 Poor overall survival HR 1.73 (1.36-2.19) 31667976 Li J Urologic tumors 20 4037 Mortality HR 1.72 (1.27-2.32) 32131764 Zhang XM Breast cancer 6 5497 Mortality HR 1.71 (1.35-1.91) 34601314 Chen F Gastric cancer resection gimmune checkpoint inhibitors 9 7615 Poor overall survival RR 1.71 (1.35-1.91) 32221737 McSharry V Epithelial ovarian cancer 6 1226 3-year survival RR 1.70 (1.80-3.50) 32221737 McSharry V Epithelial ovarian cancer 13 4262 Poor overall survival HR 1.70 (1.45-1.99) ++ 3231700 Surv A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 1.68 (1.54-1.83) ++ 3382031 Wang J Non-small cell lung cancer 6 121 Poor overall survival HR 1.61 (1.10-2.48) ++ 3382031 Wang J Non-small cell lung cancer 70 21876 Poor overall survival RR 1.61 (1.2-2.10) ++ ++ <	33997307	Li HL	Cancer	81	12731	Mortality HR	1.74 (1.46-2.07)	
11667976 Li J Urologic tumors 16 2264 Poor overall survival HR 1.73 (144-2.01) 20965167 Kim G Liver cirrhosis 20 470 Mortality HR 1.71 (125-2.33) 32131764 Chen F Gastric cancer resceiving immune checkpoint inhibitors 9 740 Poor 1-year overall survival rate HR 1.71 (135-2.19) +++ 34165897 Deng HY Solid cancers receiving immune checkpoint inhibitors 9 740 Poor 1-year overall survival RR 1.71 (139-2.10) +++ 34165897 Deng HY Solid cancers receiving immunotherapy 6 126 3-year survival OR 1.70 (145-19) +++ 35817000 Survo A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 1.68 (154-1.83) ++ 35822276 O'Connell RM Hepatic resection for colorectall liver metastases 13 2267 Poor overall survival RR 1.61 (137-1.87) ++ 3182031 Non -small cell lung cancer 6 121 Poor overall survival RR 1.61 (134-2.10) ++ 3182037 Non -small cell lung cancer 70 21876 Poor overall survival RR </td <td>34513704</td> <td>LiS</td> <td>Cancers receiving immune checkpoint inhibitors</td> <td>19</td> <td>1763</td> <td>Poor overall survival HR</td> <td>1.73 (1.36-2.19)</td> <td></td>	34513704	LiS	Cancers receiving immune checkpoint inhibitors	19	1763	Poor overall survival HR	1.73 (1.36-2.19)	
20065187 Kim G Liver dirrhosis 20 4037 Mortality HR 172(127-232) 2131764 Zhang XM Broast cancer 6 5497 Mortality HR 171(125-233) 34601314 Chen F Gastric cancer resection 20 7615 Poor overall survival RR 171(125-233) 34601314 Chen F Gastric cancer resection 20 7615 Poor overall survival RR 171(125-213) 32221737 MicSharry V Epithelial ovarian cancer 18 3193 Poor overall survival RR 170(10.80-350) 32221737 MicSharry V Epithelial ovarian cancer 13 4262 Poor overall survival HR 168(15.4-1.89) 3281700 Surva A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 168(1.10-2.48) 3581700 Surva A Melanoma receiving annunotherapy 6 719 Poor overall survival HR 163(1.13-2.33) 3582031 Wang J Non-small cell lung cancer 9 576 Poor 1-year survival RR 161(1.24-2.10) 31782039 Su H Gastrointestinal cancer 70 21875 All-cau	31567976	-Ti J	Urologic tumors	16	2264	Poor overall survival HR	1 73 (1 48-2 01)	
32131744Zhang XMBreast cancer65497Mortality HR1.71 (1.22-2.33)34601314Chen FGastric cancer resection207615Poor overall survival RR1.71 (1.33-1.91)34601314Chen FGastric cancer resection9740Poor 1-year overall survival RR1.71 (1.33-2.10)32221737McSharry VEpithelial ovarian cancer183193Poor overall survival RR1.70 (0.80-3.50)32221737McSharry VEpithelial ovarian cancer183193Poor overall survival RR1.70 (1.45-1.99)32461543Sophier PREsophageal cancer134262Poor overall survival HR1.70 (1.45-1.99)34615154Fang PEsophageal cancer415965Poor overall survival HR1.667 (1.11-2.52)3581700Surov AMelanoma receiving immunotherapy6719Poor overall survival HR1.651 (1.10-2.48)30346030Deng HYNon-small cell lung cancer61213Poor overall survival RR1.651 (1.36-1.91)31796090Su HGastrichestinal cancer7021876Alf-cause mortality HR1.601 (1.37-1.87)31796090Su HGastrichestinal cancer7021876Alf-cause mortality HR1.60 (1.27-1.87)31280871Xia WTrauma10286730 dags mortality RR1.60 (1.27-1.87)31280871Kia WTrauma10286730 dags mortality RR1.60 (1.27-1.87)31294094Xu LHepatocellular cancinoma	29065187	Kim G	Liver cirrhosis	20	4037	Mortality HR	1 72 (1 27-2 32)	
ZachonDiscrete cancer207615Poor overall survival rate HR1.71 (1:33-191)34166897Deng HYSolid cancers receiving immune checkpoint inhibitors672615Poor overall survival rate HR1.71 (1:33-191)34166897Deng HYSolid cancers receiving immune checkpoint inhibitors672615Poor overall survival RR1.71 (1:33-191)34166897Deng HYSolid cancers receiving immune checkpoint inhibitors672615Poor overall survival RR1.71 (1:33-191)3984753Yang ZGastric cancer1334262Poor overall survival RR1.70 (1:33-2:17)3984753Yang ZGastric cancer134262Poor overall survival RR1.67 (1:14-5:19)3984753Surov AMelanoma receiving immuncherapy6719Poor overall survival RR1.67 (1:14-5:19)3982730Surov AMelanoma receiving immuncherapy6710 Poor overall survival RR1.61 (1:12-5:10)39328031Jones KAbdominal surgery245267Poor 1-year survival RR1.61 (1:24-2:10)31760509Su HGastricinestinal cancer7021875All-cause mortality HR1.60 (1:21-2:13)31260871Xia WTrauma10266730 days mortality RR1.60 (1:21-2:13)31260871Xia WTrauma10266730 days mortality RR1.60 (1:21-2:13)31260871Xia WTrauma10266730 days mortality RR1.60 (1:21-2:13)31260871Solid Um Resectab	32131764	Zhang XM	Breast cancer	6	5497	Mortality HR	1 71 (1 25-2 33)	
Shell Fr Gashic Carlos resculut 20 7613 Pool overall survival RR 1.71 (1.39-2.10) 3166897 Dang HY Solid cancers receiving immune checkpoint inhibitors 9 740 74	24601214	Chan E	Castria concer reportion	20	7615	Deer everall everywel rete HD	1.71 (1.20 2.00)	
94106097 Defig HT Solid Carlos receiving immune checkpoint innolitors 9 740 Poor 1-year overall survival RR 1.71 (1.39–2.10) 92846548 Boshier PR Esophageal cancer 18 3193 Poor overall survival HR 1.70 (1.43–2.10) 92846548 Boshier PR Esophageal cancer 13 4262 Poor overall survival HR 1.70 (1.45–1.83) +++ 36415154 Fang P Esophageal cancer 41 5965 Poor overall survival HR 1.68 (1.54–1.83) +++ 3581700 Surov A Melanoma receiving immuncherapy 6 719 Poor overall survival HR 1.65 (1.10–2.48) 35822276 O'Connell RM Hepatic resection for colorectal liver metastases 13 2936 Poor 1-year survival RR 1.61 (1.36–1.91) +++ 3182031 Wang J Non-small cell lung cancer 6 1213 Poor overall survival RR 1.61 (1.24–2.10) +++ 31760609 Su H Gastricinetistinal cancer 70 21875 All-cause mortalily HR 1.60 (1.37–1.87) +++ 3182031 Wang J Non-small cell lung cancer 21 3966 Poor overall survival	34601314	Cheft F	Gastric cancer resection	20	7015		1.71 (1.55-1.91)	
22221137 Micsharty V Epithelial ovarian Cancer 6 1226 3-year survival CR 1.70 (0.80-3.50) 29846548 Boshier PR Esophageal cancer 13 4262 Poor overall survival HR 1.70 (0.80-3.50) 29887739 Yang Z Gastric cancer 41 5965 Poor overall survival HR 1.70 (1.45-1.99) 29887739 Surov A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 1.68 (1.54-1.83) 30348603 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival RR 1.63 (1.13-2.33) 30348603 Deng HY Non-small cell lung cancer 9 576 Poor overall survival RR 1.61 (1.24-2.10) 31382031 Wang J Non-small cell lung cancer 9 576 Poor overall survival RR 1.61 (1.124-2.10) 3128097 Xia W Trauma 10 2876 73 0 days mortality RR 1.60 (1.17-1.87) Her 3128097 Xia W Trauma 10 2866 Poor overall survival RR 1.56 (1.25-1.95) Her 30496385 Deng HY Resectable esophageal cancer 5 783 Poor	34100897	Deng HY	Solid cancers receiving immune checkpoint inhibitors	9	740	Poor 1-year overal survival RR	1.71 (1.39-2.10)	
29986739 Bosnier PK Esophageal cancer 18 3193 Poor Overall survival HR 1.70 (1.35-2.17) 36415154 Fang P Esophageal cancer 41 5965 Poor overall survival HR 1.68 (1.54-1.83) 35817000 Surov A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 1.65 (1.10-2.48) 35922276 O'Connell RM Hepatic resection for colorectal liver metastases 13 2936 Poor overall survival HR 1.65 (1.10-2.48) 30348603 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival RR 1.61 (1.36-1.91) 3176009 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.27-1.87) 31280971 Xia W Trauma 10 2867 30 days mortality RR 1.60 (1.27-1.83) ++ 35794004 Jogiat UM Resectable esophageal cancer 21 3966 Poor overall survival HR 1.56 (1.25-1.85) ++ 35794004 Jogiat UM Resectable esophageal cancer 21 3966 Poor overall survival HR 1.56 (1.25-1.85) ++ 30266663 </td <td>32221737</td> <td>McSharry v</td> <td>Epithelial ovarian cancer</td> <td>0</td> <td>1220</td> <td>3-year survival OR</td> <td>1.70 (0.80-3.50)</td> <td></td>	32221737	McSharry v	Epithelial ovarian cancer	0	1220	3-year survival OR	1.70 (0.80-3.50)	
29987739 Yang Z Gastric cancer 13 4262 Poor overall survival HR 1.70 (1.45-1.99) 58171500 Surov A Melanoma receiving immuncherapy 6 719 Poor overall survival HR 1.67 (1.11-2.52) 58171000 Surov A Melanoma receiving immuncherapy 6 719 Poor overall survival HR 1.67 (1.11-2.52) 30348603 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival HR 1.63 (1.13-2.33) 30348603 Deng HY Non-small cell lung cancer 9 576 Poor 1-year survival RR 1.61 (1.36-1.91) 31726090 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.37-1.87) 3128031 Xia W Trauma 10 2867 20 days mortality RR 1.65 (1.24-2.10)	29846548	Boshier PR	Esophageal cancer	18	3193	Poor overall survival HR	1.70 (1.33-2.17)	+ - +
36415154Fang PEsophageal cancer415965Poor overall survival HR1.68 (1.54-1.63)35817000Surov AMelanoma receiving immunotherapy6719Poor overall survival HR1.67 (1.11-2.52)30348603Deng HYNon-small cell lung cancer61213Poor overall survival HR1.63 (1.10-2.48)30348031Wang JNon-small cell lung cancer61213Poor overall survival RR1.61 (1.36-1.91)3182031Wang JNon-small cancer9576Poor 1-year survival RR1.61 (1.34-1.87)31726009Su HGastrointestinal cancer7021875All-cause mortality HR1.60 (1.37-1.87)31280971Xia WTrauma10286730 days mortality RR1.60 (1.21-2.13)30496385Deng HYEsophageal cancer111520Poor overall survival HR1.57 (1.34-1.84)3209496Xu LHepatocellular carcinoma61420Poor overall survival HR1.56 (1.25-1.95)3763026663Mintzinas IPanceatre ceiving immune checkpoint inhibitors262501Poor overall survival HR1.55 (1.21-1.89)30264663Mintzinas IPanceatic cancer5783Poor overall survival HR1.48 (1.26-1.74)+++3682087Shachar SSSolid tumours387843Poor overall survival HR1.44 (1.22-1.62)+++37640640Kie HColorectal cancer1915889Poor overall survival HR1.40 (1.20-1.64)+++376	29987739	Yang Z	Gastric cancer	13	4262	Poor overall survival HR	1.70 (1.45-1.99)	H=1
35817000 Surov A Melanoma receiving immunotherapy 6 719 Poor overall survival HR 1.67 (1.11–2.52) 30348003 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival RR 1.63 (1.13–2.33) 30348003 Deng HY Non-small cell lung cancer 9 576 Poor 1-year survival RR 1.61 (1.36–1.91) 31780203 Wang J Non-small cell lung cancer 9 576 Poor 1-year survival RR 1.61 (1.24–2.10) +++ 31780203 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.37–1.87) +++ 31280971 Xia W Trauma 10 2867 30 days mortality RR 1.60 (1.21–2.13) +++ 30349603 Xu L Hepatocellular carcinoma 6 1420 Poor overall survival HR 1.55 (1.25–1.85) +++ 31280946 Xu L Hepatocellular cancinoma 6 1420 Poor overall survival HR 1.55 (1.25–1.85) +++ 31280496 Xu L Hepatocellular cancer 11 2297 Poor overall survival HR 1.55 (1.32–1.82) +++	36415154	Fang P	Esophageal cancer	41	5965	Poor overall survival HR	1.68 (1.54-1.83)	
35922276 O'Connell RM Hepatic resection for colorectal liver metastases 13 2936 Poor overall survival RR 1.65 (1.10–2.48) 30348603 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival RR 1.61 (1.36–1.91) 3182031 Wang J Non-small cell lung cancer 9 576 Poor 1-year survival RR 1.61 (1.34–2.10) 31796090 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.37–1.87) 31280971 Xia W Trauma 10 2867 30 days mortality RR 1.60 (1.21–2.13) 330496335 Deng HY Esophageal cancer 11 1520 Poor overall survival HR 1.56 (1.25–1.95) 33209496 Xu L Hepatocellular carcinoma 6 1420 Poor overall survival HR 1.56 (1.32–1.82) + 36151845 Jogiat UM Resectable esophageal cancer 5 783 Poor overall survival HR 1.56 (1.22–1.82) + 26882087 Shachar SS Solid tumours 38 7843 Poor overall survival HR 1.44 (1.32–1.56) + 3768205 Ibilib	35817000	Surov A	Melanoma receiving immunotherapy	6	719	Poor overall survival HR	1.67 (1.11-2.52)	·
3034803 Deng HY Non-small cell lung cancer 6 1213 Poor overall survival RR 1.63 (1.13–2.33) 30348073 Jones K Abdominal surgery 24 5267 Poor 1-year survival RR 1.61 (1.36–1.91) 3182031 Wang J Non-small cell lung cancer 9 576 Poor 1-year survival RR 1.61 (1.24–2.10) 3178009 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.27–1.87) 30496355 Deng HY Esophageal cancer 11 1520 Poor overall survival HR 1.55 (1.35–1.85) 303209496 Xu L Hepatocellular carcinoma 6 1420 Poor overall survival HR 1.55 (1.25–1.95) 30337889 Takenaka Y Cancer receiving immune checkpoint inhibitors 26 2501 Poor overall survival HR 1.55 (1.22–1.82) 30268663 Mintziras I Pancreatic cancer 11 2297 Poor overall survival HR 1.46 (1.26–1.74) 3178004 Jogiat UM Unresectable osophageal cancer 5 783 Poor overall survival HR 1.46 (1.26–1.74) 30266663 Mintziras I Pancreatic cancer <td>35922276</td> <td>O'Connell RM</td> <td>Hepatic resection for colorectal liver metastases</td> <td>13</td> <td>2936</td> <td>Poor overall survival HR</td> <td>1.65 (1.10-2.48)</td> <td>·</td>	35922276	O'Connell RM	Hepatic resection for colorectal liver metastases	13	2936	Poor overall survival HR	1.65 (1.10-2.48)	·
28386715Jonës KAbdominal surgery245267Poor 1-year survival RR1.61 (1.36-1.91)33182031Wang JNon-small cell lung cancer9576Poor 1-year survival RR1.61 (1.36-1.91)33182031Wang JNon-small cell lung cancer9576Poor 1-year survival RR1.61 (1.37-1.87)31280971Xia WTrauma10286730 days mortality RR1.60 (1.37-1.87)31280971Xia WTrauma10286730 days mortality RR1.60 (1.27-2.13)31290946Xu LHepatocellular carcinoma61420Poor overall survival HR1.58 (1.35-1.85)35794004Jogiat UMResectable esophageal cancer213966Poor overall survival HR1.55 (1.25-1.95)3437889Takenaka YCancer receiving immune checkpoint inhibitors262501Poor overall survival HR1.56 (1.25-1.95)36151845Jogiat UMUnresectable esophageal cancer5783Poor overall survival HR1.58 (1.22-1.82)32626663Mintzinas IPancreatic cancer112297Poor overall survival HR1.44 (1.22-1.62)33763255Ibilibor CRadical cystectomy51447All-cause mortality HR1.40 (1.22-1.62)35747410HColorectal cancer1915889Poor overall survival HR1.40 (1.22-1.62)35784255Ibilibor CRadical cystectomy51447All-cause mortality HR1.40 (1.22-1.62)35784044Sutton EHColorectal	30348603	Deng HY	Non-small cell lung cancer	6	1213	Poor overall survival RR	1.63 (1.13-2.33)	·
33182031 Wang J Non-small cell lung cancer 9 576 Poor 1-jear survival RR 1.61 (1.24-2.10) Image: concert concent concert concert concert concert concert concert concert conce	28386715	Jones K	Abdominal surgerv	24	5267	Poor 1-vear survival RR	1.61 (1.36-1.91)	
31796090 Su H Gastrointestinal cancer 70 21875 All-cause mortality HR 1.60 (1.37-1.87) 31280971 Xia W Trauma 10 2867 30 days mortality HR 1.60 (1.37-1.87) 31280971 Xia W Trauma 10 2867 30 days mortality HR 1.60 (1.37-1.87) 31280971 Xia W Trauma 10 2867 30 days mortality HR 1.60 (1.37-1.87) 31280971 Xia W Hepatocellular carcinoma 6 1420 Poor overail survival HR 1.55 (1.32-1.85) 33209496 Xu L Hepatocellular carcinoma 6 1420 Poor overail survival HR 1.55 (1.25-1.32) 34337889 Takenaka Y Cancer receiving immune checkpoint inhibitors 26 2501 Poor overail survival HR 1.55 (1.32-1.82) 30266663 Mintziras I Pancreatic cancer 11 2297 Poor overail survival HR 1.48 (1.26-1.74) H 2682087 Shachar SS Solid tumours 38 7843 Poor overail survival HR 1.44 (1.32-1.66) H 2682087 Shachar SS Solid tumours 5 1447	33182031	Wang J	Non-small cell lung cancer	9	576	Poor 1-year survival RR	1.61 (1.24-2.10)	
31280971 Xia W Trauma 10 2867 30 days mortality RR 1.60 (1.21-2.13) 30496385 Deng HY Esophageal cancer 11 1520 Poor overail survival HR 1.58 (1.35-1.85) 35209496 Xu L Hepatocellular carcinoma 6 1420 Poor overail survival HR 1.55 (1.32-1.85) 35794004 Jogiat UM Resectable esophageal cancer 21 3966 Poor overail survival HR 1.55 (1.32-1.85) 34337889 Takenaka Y Cancer receiving immune checkpoint inhibitors 26 2501 Poor overail survival HR 1.55 (1.32-1.85) 30266663 Mintziras I Pancreatic cancer 11 2297 Poor overail survival HR 1.44 (1.22-1.65) 30266663 Mintziras I Pancreatic cancer 19 15889 Poor overail survival HR 1.44 (1.22-1.65) 31406490 Xia H Colorectal cancer 19 15889 Poor overail survival HR 1.40 (1.25-1.86) 31763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.41 (1.22-1.62) ++ 31763254 Ibilibor C Radical cystectomy	31796090	SuH	Gastrointestinal cancer	70	21875	All-cause mortality HR	1 60 (1 37-1 87)	
AutomicThe and to approximationTo LossLossLossLossLoss320946835Deng HYEsophageal cancer111520Poor overall survival HR1.56 (1.35-1.85)Image: Concertain the approximation of the approximat	31280971	XiaW	Trauma	10	2867	30 days mortality RR	1 60 (1 21-2 13)	
30350303 Deprint Esophageal cancer 11 1220 Poor overall survival HR 1.35 (1.35-1.63) 35794004 Jogiat UM Resectable esophageal cancer 21 3966 Poor overall survival HR 1.55 (1.32-1.83) 35794004 Jogiat UM Resectable esophageal cancer 21 3966 Poor overall survival HR 1.55 (1.32-1.82) 36151845 Jogiat UM Unresectable oesophageal cancer 5 783 Poor overall survival HR 1.51 (1.21-1.89) 30266663 Mintziras I Pancreatic cancer 11 2297 Poor overall survival HR 1.44 (1.22-1.60) 30266663 Shachar SS Solid tumours 38 7843 Poor overall survival HR 1.44 (1.22-1.60) 33763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.44 (1.22-1.62) 31763256 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.40 (1.20-1.64) 32747410 Allanson ER Gynaecology cancer 27 4266 Poor overall survival HR 1.30 (1.03-1.72) 32474710 Allanson ER Gynaecology cancer <td< td=""><td>20406295</td><td>Dong HV</td><td>Econhagoal cancor</td><td>11</td><td>1520</td><td>Poor overall curvival HP</td><td>1.50 (1.25-1.95)</td><td></td></td<>	20406295	Dong HV	Econhagoal cancor	11	1520	Poor overall curvival HP	1.50 (1.25-1.95)	
53203990 AU L neptatocellular calcinolia 6 1420 Pool Overali survival HR 1.51 (1.34-1.64) 53794004 Jogiat UM Resctable eosophageal cancer 21 3966 Poor overali survival HR 1.55 (1.32-1.62) 34337889 Takenaka Y Cancer receiving immune checkpoint inhibitors 26 2501 Poor overali survival HR 1.55 (1.32-1.62) 36151845 Jogiat UM Unresectable osophageal cancer 5 783 Poor overali survival HR 1.44 (1.26-1.74) 20826663 Mintziras I Pancreatic cancer 11 2297 Poor overali survival HR 1.44 (1.32-1.62) 2082087 Shachar SS Solid tumours 38 7843 Poor overali survival HR 1.44 (1.32-1.62) 33763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.40 (1.25-1.58) 34406490 Xie H Colorectal cancer 19 15889 Poor overali survival HR 1.40 (1.25-1.58) 32747410 Allanson ER Gynaecology cancer 27 4246 Poor overali survival HR 1.30 (1.03-1.72) 324249675 Jin SB Esophageal cancer<	22200406	Deligiti	Heneteeelluler eereineme	6	1420	Poor overall survival HD	1.50(1.55-1.05)	
363794004 Joglat UM Resectable esophageal cancer 21 3960 Poor overall survival HR 1.56 (1.25-1.95) 361794004 Joglat UM Unresectable oesophageal cancer 26 2501 Poor overall survival HR 1.55 (1.32-1.85) 36151445 Jogiat UM Unresectable oesophageal cancer 5 783 Poor overall survival HR 1.51 (1.21-1.89) 30266663 Mintziras Pancreatic cancer 11 2297 Poor overall survival HR 1.44 (1.32-1.56) 303763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.41 (1.22-1.62) 31406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25-1.58) 31763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.40 (1.25-1.58) 31763256 Ibilibor C Rojnecological cancer 19 15889 Poor overall survival HR 1.40 (1.25-1.58) 35194194 Sutton EH Gynaecology cancer 27 4286 Poor overall survival HR 1.40 (1.20-1.64) 35282920 Dakis K Endovascular aortic aneurys	35209490			04	1420		1.57 (1.54-1.64)	
34337889 Takenaka Y Cancer receiving immune checkpoint inhibitors 26 2501 Poor overall survival HR 1.55 (1.22-1.82) 36151845 Jogiat UM Unresectable oesophageal cancer 5 783 Poor overall survival HR 1.51 (1.21-1.82) 30266663 Mintziras I Pancreatic cancer 11 2297 Poor overall survival HR 1.48 (1.26-1.74) 26882087 Shachar SS Solid tumours 38 7843 Poor overall survival HR 1.48 (1.22-1.62) 3763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.41 (1.22-1.62) 376439 Poor overall survival HR 1.40 (1.25-1.58) ++ 34406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25-1.64) 35194194 Sutton EH Gynecological cancer 13 2446 Poor overall survival HR 1.30 (1.08-1.64) 322747410 Allanson ER Gynecological cancer 11 1485 Poor overall survival HR 1.30 (1.08-1.64) 322476975 Jin SB Esophageal cancer 26 4515 Poor overall survival HR	35794004	Jogiat UM	Resectable esophageal cancer	21	3966	Poor overall survival HR	1.56 (1.25-1.95)	
36151845 Jogiat UM Unresectable oesophageal cancer 5 783 Poor overall survival HR 1.51 (1.21-1.89) 30266663 Mintziras I Pancreatic cancer 11 2297 Poor overall survival HR 1.48 (1.26-1.74) 26882087 Shachar SS Solid tumours 38 7843 Poor overall survival HR 1.44 (1.32-1.56) 33763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.44 (1.32-1.62) 3406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25-1.58) 35194194 Sutton EH Gynaecology cancer 27 4286 Poor overall survival HR 1.40 (1.20-1.64) 35282290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.30 (1.03-1.72) 324249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.20 (1.04-1.54) 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.21 (1.04-1.20)	34337889	Такепака т	Cancer receiving immune checkpoint inhibitors	26	2501	Poor overall survival HR	1.55 (1.32-1.82)	
30266663 Mintziras I Pancreatic cancer 11 2297 Poor overall survival HR 1.48 (1.26-1.74) Image: Concerned and the concerned and	36151845	Jogiat UM	Unresectable oesophageal cancer	5	783	Poor overall survival HR	1.51 (1.21-1.89)	·
26882087 Shachar SS Solid tumours 38 7843 Poor overall survival HR 1.44 (1.32–1.56) ++ 33763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.41 (1.32–1.56) ++ 34406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25–1.58) ++ 35194194 Sutton EH Gynaecology cancer 27 4286 Poor overall survival HR 1.40 (1.20–1.64) ++ 352474710 Allanson ER Gynaecological cancer 13 2446 Poor overall survival HR 1.30 (1.03–1.72) 352828290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.29 (1.08–1.54) 34249675 Jin SB Esophageal cancer 26 4515 Poor overall survival HR 1.29 (1.08–1.54) 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.21 (1.04–1.20)	30266663	Mintziras I	Pancreatic cancer	11	2297	Poor overall survival HR	1.48 (1.26-1.74)	
33763255 Ibilibor C Radical cystectomy 5 1447 All-cause mortality HR 1.41 (1.22–1.62) +++ 34406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25–1.62) +++ 5194194 Sutton EH Gynaecology cancer 27 4266 Poor overall survival HR 1.40 (1.20–1.64) +++ 32747410 Allanson ER Gynecological cancer 13 2446 Poor overall survival HR 1.33 (1.08–1.64) +++ 35288290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.20 (1.08–1.54) +++ 34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08–1.54) +++ 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.29 (1.04–1.20) +++	26882087	Shachar SS	Solid tumours	38	7843	Poor overall survival HR	1.44 (1.32-1.56)	+=+
34406490 Xie H Colorectal cancer 19 15889 Poor overall survival HR 1.40 (1.25-1.58) +++ 35194194 Sutton EH Gynaecology cancer 27 4286 Poor overall survival HR 1.40 (1.25-1.58) +++ 32747410 Allanson ER Gynaecology cancer 13 2446 Poor overall survival HR 1.33 (1.08-1.64) +++ 35288290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.30 (1.03-1.72) 34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08-1.54) 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.12 (1.04-1.20)	33763255	Ibilibor C	Radical cystectomy	5	1447	All-cause mortality HR	1.41 (1.22-1.62)	→= →
35194194 Sutton EH Gynaecology cancer 27 4286 Poor overall survival HR 1.40 (120-164) +++ 3274710 Allanson ER Gynaecology cancer 13 2446 Poor overall survival HR 1.33 (1.08-1.64) +++ 32747410 Allanson ER Gynaecology cancer 13 2446 Poor overall survival HR 1.33 (1.08-1.64) +++ 32747410 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.20 (1.03-1.72) +++ 34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08-1.54) +++ 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.12 (1.04-1.20)	34406490	Xie H	Colorectal cancer	19	15889	Poor overall survival HR	1.40 (1.25-1.58)	
32747410 Allanson ER Gynecological cancer 13 2446 Poor overall survival HR 1.33 (1.08–1.64) 328290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor overall survival HR 1.33 (1.08–1.64) 34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08–1.54) 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.12 (1.04–1.20)	35194194	Sutton EH	Gynaecology cancer	27	4286	Poor overall survival HR	1.40 (1.20-1.64)	
35288290 Dakis K Endovascular aortic aneurysm repair 11 2385 Poor 5-year survival OR 1.30 (1.03-1.72) 34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08-1.54) 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.12 (1.04-1.20)	32747410	Allanson ER	Gynecological cancer	13	2446	Poor overall survival HR	1.33 (1.08-1.64)	
34249675 Jin SB Esophageal cancer 11 1485 Poor overall survival HR 1.29 (1.08-1.54) Image: Concert survival HR 35077542 Chen F Esophageal cancer 26 4515 Poor overall survival HR 1.29 (1.08-1.54) Image: Concert survival HR	35288290	Dakis K	Endovascular aortic aneurysm repair	11	2385	Poor 5-year survival OR	1.30 (1.03-1.72)	
Statute The food operation within the food operation wit	34249675	lin SB	Esophageal cancer	11	1485	Poor overall survival HR	1 29 (1 08-1 54)	→
	35077542	Chen F	Esophageal cancer	26	4515	Poor overall survival HP	1 12 (1 0/-1 20)	
	00011042	01011	Loophagoar oanoor	20	-1010		1.12(1.07 1.20)	
								0.0 0 4

Fig. 2. Mortality and survival associated with sarcopenia in patients with different medical conditions. HR, hazard ratio; OR, odds ratio; RR, relative risk.

diseases, like diabetes and cardiovascular disease, some hypotheses concerning chronic inflammation [46], excessive oxidative stress [47], insulin resistance [48], endothelial dysfunction [47], and liver dysfunction [49], have been proposed to explain these associations. However, given that sarcopenia and metabolic diseases often coexist among populations and possibly have mutual influences, it is difficult to determine which is the cause of the link. Even though some studies found that a prior diagnosis of sarcopenia was associated with an increased risk of cardiovascular disease [50,51], whether the observed association was the consequences of shared risk factors, or reflect a causal association needs further research.

There were differences in inflammation [52], clinical biomarkers [53], blood 25-hydroxyvitamin D [54], adiponectin [55], and pulse wave velocity [56] between sarcopenic patients and non-sarcopenic individuals. These associations need to be confirmed in prospective cohort studies or other studies that can minimize reverse causation and strengthen causality. In addition, gut microbiota may play a role in the development of sarcopenia [57]. Thus, whether probiotics, prebiotics, and bacterial products have preventive and therapeutic potentials

deserves exploration.

4. Limitations

Several limitations of this study need discussion. First, this is a review of published meta-analyses. Thus, some novel risk factors and rare consequences of sarcopenia may have been missed due to a few original studies on these topics. Second, even though this review identified many factors and morbidities associated with sarcopenia, the listed associations need to be carefully considered, particularly associations with high heterogeneity between studies or from low-quality studies. Third, this review was mainly based on evidence from observational studies, which cannot provide information on causality of the observed associations.

5. Future directions

5.1. Omics for sarcopenia

There are genome-wide association analyses on components of

Table 4

Consequences of sarcopenia in general populations.

PMID	First author	Consequences of sarcopenia	No. of studies	Ν	Heterogeneity
28778327	Liu P	All-cause mortality $HR = 1.60 (1.24-2.06)$	6	7367	Low
30420343	Zhang X	All-cause mortality $HR = 1.86 (1.42-2.45)$	6	1494	Low
28647519	Kelley GA	All-cause mortality $OR = 3.64 (2.94-4.51)$	12	14,169	Low
34315158	Xu J	Mortality HR = 2.00 (1.71–2.34)	56	42,108	Moderate
36362701	Su YC	Mortality HR = 9.57 (3.17–28.94)	38	27,226	High
28095426	Beaudart C	Mortality OR = 3.60 (2.96–4.37)	17	>22,000	Moderate
26844538	Chang SF	Mortality HR = 1.87 (1.61–2.18)	10	3797	Low
35670963	Chen X	Cognitive impairment $OR = 1.75 (1.57-1.95)$	26	18,788	High
27816484	Chang KV	Cognitive impairment $OR = 2.25 (1.21-4.17)$	7	5994	High
31917049	Peng TC	Cognitive impairment $OR = 2.25 (1.70-2.97)$	15	10,410	Low
31233073	Cabett Cipolli G	Cognitive impairment $OR = 2.50 (1.26-4.92)$	6	7045	High
33909650	Teng Z	Osteopenia OR = 2.08 (1.66-2.60)	25	47,744	High
36401390	Yu X	Osteoporosis OR = 3.06 (2.30-4.08)	56	796,914	High
30665817	Zhang X	Falls OR = 1.52 (1.32–1.77)	10	10,073	Moderate
30993881	Yeung SSY	Falls OR = 1.89 (1.33-2.68)	33	52,838	Moderate
32115209	Chen H	Fracture HR = 1.50 (1.08–2.08)	5	27,990	High
29500527	Zhang Y	Fracture RR = 1.34 (1.13–1.58)	9	31,513	Low
34674498	Nielsen BR	Fracture RR = 1.37 (1.18–1.59)	4	7257	High
36362701	Su YC	Fractures HR = 9.66 (5.07–18.38)	38	27,226	High
30993881	Yeung SSY	Fractures OR = 1.71 (1.44–2.03)	33	52,838	Low
33491032	Huang P	Hip fractures $HR = 1.42 (1.18-1.71)$	5	23,359	Moderate
28647519	Kelley GA	Functional decline $OR = 2.58 (1.33-4.99)$	12	14,169	High
28095426	Beaudart C	Functional decline $OR = 3.03$ (1.80–5.12)	17	>22,000	High
36362701	Su YC	Hospitalization $HR = 11.80$ (4.86–28.65)	38	27,226	High
30134867	Zhang X	Hospitalization $HR = 1.57 (1.26-1.94)$	5	2832	Low
29549649	Zhao Y	Hospitalization $RR = 1.40$ (1.04–1.89)	8	4174	Moderate
29547573	Zhang H	Metabolic syndrome $OR = 2.01$ (1.63–2.47)	12	35,581	High
34652699	Veronese N	Diabetes OR = 2.07 (1.40-3.62)	17	54,676	Low
30048963	Pan X	NAFLD $OR = 1.29 (1.12 - 1.49)$	6	19,024	High
29451179	Wijarnpreecha K	NAFLD $OR = 1.54$ (1.05–2.26)	5	27,804	High
30048963	Pan X	Fibrosis OR = 1.57 (1.29–1.90)	6	19,024	Low
32762638	Bai T	Hypertension $OR = 1.29 (1.00-1.67)$	12	21,301	Moderate
28633395	Chang KV	Depression OR = 1.82 (1.16–2.86)	10	33,030	High
30272106	Zhao WT	Dysphagia OR = 4.06 (2.27–7.29)	5	913	Low

HR, hazard ratio; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; RR, relative risk. Heterogeneity was assessed by reported I^2 statistic (low 0–24.9 %; moderate 25–74.9 %; high 75–100 %).

sarcopenia, such as muscle mass (fat-free mass) [58] and grip strength [59]. However, the genetic architecture underlying sarcopenia considering both muscle mass and strength remains unclear [60]. A large-scale international genetic consortium collecting unified data on sarcopenia is warranted. Similarly, more studies are needed on epigenetics, transcriptomics, proteomics, metabolomics, and microbiome on sarcopenia. Such studies could deepen the understanding of the etiological basis of sarcopenia from genetic and molecular perspectives as well as facilitate prevention strategy formulation and drug development for the disease. In addition, potential gene-environmental interactions in sarcopenia are of interest to explore.

5.2. High-quality cohort studies and Mendelian randomization analysis

High-quality prospective cohort studies are lacking in this field, especially concerning the exploration of the risk factors for sarcopenia. Except for focusing on clinical patients who are vulnerable to sarcopenia, cohort studies with accurate measurements of muscle quantity and function in generally healthy population are needed to provide evidence to formulate primary prevention strategies. In addition, Mendelian randomization analysis is a widely used epidemiological tool that can strengthen causal inference by using genetic variants as unbiased instrumental variables for the potential risk factor [61]. The causality of observed associations for sarcopenia should be examined using Mendelian randomization analysis.

6. Conclusion

This review summarized evidence on epidemiological features of sarcopenia (Fig. 3). Even though the prevalence of sarcopenia varies

according to definition used, it is a prevalent disease among the elderly and patients with varying medical conditions. Sarcopenia is associated with a high risk of a wide range of adverse health outcomes, including poor survival rate, postoperative complications, and longer hospitalization in patients as well as falls and facture, metabolic disorders, cognitive impairment, and mortality in general populations. Physical inactivity, malnutrition, smoking, extreme sleep duration, and diabetes and several other comorbidities were associated with an increased risk of sarcopenia. However, these associations were mainly based on noncohort observational studies and require confirmation. High-quality cohort, omics, and Mendelian randomization studies are needed to understand the etiological basis of sarcopenia with the aims of preventing and better managing the disease.

Funding

This study did not receive any funding.

CRediT authorship contribution statement

Shuai Yuan: Conceptualization, Methodology, Data curation, Investigation, Writing – original draft, Visualization. **Susanna C. Larsson:** Conceptualization, Methodology, Investigation, Resources, Writing – review & editing, Supervision.

Declaration of competing interest

The authors have no conflict of interest to declare.

Table 5

Risk factors for sarcopenia.

PMID	First author	Risk factor	No. of studies	Ν	Heterogeneity
36443946	Liu C	Obesity $OR = 0.66 (0.48 - 0.91)$	34	-	High
		Obesity $OR = 3.08 (1.65-5.74)$ after adjusting for muscle mass			0
27170042	Steffl M	Alcohol consumption $OR = 0.77 (0.67-0.88)$	13	13.155	Moderate
36014771	Hong SH	Alcohol consumption $OR = 1.00 (0.83 - 1.20)$	19	422.870	Moderate
28553092	Steffl M	Physical inactive $OB = 2.22 (1.82-2.70)$	25	40.007	Moderate
30409494	Shen V	Malnutrition OR -1.74 (1.36–2.24)	16	3585	Moderate
35096921	Zhang V	Omega-3 PUFAs highest vs. lowest OR $= 0.41 (0.26-0.65)$	6	6648	Moderate
00000021	Zinning T	Omega-6 PUFAs highest vs. lowest $OR = 0.64 (0.33-1.24)$	0	0010	moderate
31832082	Pourmotabled A	< 6 v s - 6 - 8 h OR - 1.71 (1.11 - 2.64)	4	17 551	Moderate
51052702	i ourniotabbeu A	8 us = 6.8 h OP = 1.52 (1.23 + 1.92)	7	17,551	Moderate
34050843	Gao O	Age in years $OR = 1.12 (1.10-1.13)$	68	98 502	Moderate to high
34333043	010 Q	Equals $OP = 1.12 (1.10 - 1.13)$	00	50,502	woderate to mgn
		$\frac{1}{100} = 1.10 (0.30 - 1.51)$			
		Overweight (checity $OP = 0.27 (0.17, 0.44)$			
		Simplify OP = $1.20(1.10, 1.21)$			
		Shioking $OR = 1.20 (1.10 - 1.21)$			
		Alcohol consumption $OR = 0.92 (0.84 - 1.01)$			
		Physical machine $OR = 1.73 (1.48 - 2.01)$			
		Mainutrition $OR = 2.99 (2.40-3.72)$			
		Long sleep duration $OR = 2.30 (1.37 - 3.86)$			
		Short sleep duration $OR = 3.32 (1.86-5.93)$			
		Diabetes $OR = 1.40 (1.18 - 1.66)$			
		Cognitive impairment $OR = 1.62 (1.05-2.51)$			
		Heart diseases $OR = 1.14 (1.00 - 1.30)$			
		Respiratory diseases $OR = 1.22 (1.09-1.36)$			
		Osteopenia $OR = 2.73 (1.63 - 4.57)$			
		Osteoarthritis $OR = 1.33 (1.23 - 1.44)$			
		Disability for activities of daily living $OR = 1.49 (1.15-1.92)$			
		Depression $OR = 1.46 (1.17 - 1.83)$			
		Falls $OR = 1.28 (1.14 - 1.44)$			
		Anorexia $OR = 1.50 (1.14 - 1.96)$			
		Anemia $OR = 1.39 (1.06 - 1.82)$			
34652699	Veronese N	Diabetes $OR = 1.64$ (1.20–2.22)	17	54,676	Moderate
32772138	Anagnostis P	Type 2 diabetes $OR = 1.55 (1.25 - 1.91)$	15	6526	Moderate
35002965	Qiao YS	Diabetes $OR = 2.09 (1.62 - 2.70)$	7	6783	Moderate
		Diabetic complications $OR = 2.09 (1.62-2.70)$			Low
34095184	Chung SM	Diabetes $OR = 1.64$ (1.20–2.22)	6	7022	Moderate
36053982	Wannarong T	Diabetic peripheral neuropathy $OR = 1.62$ (1.30–2.02)	5	4287	Low
34997702	Li Z	Depression $OR = 1.57 (1.32 - 1.86)$	15	16,869	High
36401390	Yu X	Osteoporosis $OR = 2.63 (1.98 - 3.49)$	17	-	High
36413812	Ponsoni A	Parkinson's disease $OR = 3.98$ (2.22–7.10)	9	1015	Moderate
34479652	Ai Y ^a	Age $OR = 4.73$ (4.30–5.19)	28	16,800	High
		Higher HbA1c $OR = 1.16 (1.05-2.47)$			
		Osteoporosis $OR = 1.16 (1.05-2.47)$			
34904651	Feng L ^a	Age OR = 1.10 (1.07–1.14)	45	12,237	Low to moderate
		Glycated hemoglobin $OR = 1.16$ (1.09–1.24)			
		Visceral fat area $OR = 1.03$ (1.02–1.05)			
		Duration of diabetes $OR = 1.06 (1.00-1.11)$			
		High-sensitivity C-reactive protein $OR = 1.33$ (1.12–1.58)			
		Exercise $OR = 0.37 (0.18-0.76)$			
		Metformin use $OR = 0.39 (0.19-0.79)$			
36403578	Zhang JZ ^a	Age $OR = 1.08 (1.05 - 1.10)$	23	2535	Low to moderate
	0	Female $OR = 0.31 (0.16 - 0.61)$			
		Lower body mass index $OR = 0.57 (0.39-0.84)$			

OR, odds ratio; PUFAs, polyunsaturated fatty acids.

^a These studies were not based on general populations (Ai Y study in patients with type 2 diabetes; Feng L study in patients with diabetes; and Zhang JZ study in patients with kidney transplantation).

TICLE IN PRE

Global prevalence

- Differing between definitions
- Around 10% to 16% in the elderly
- Higher among patient groups
 - 18% in diabetes to 66% in unresectable esophageal cancer
- **Risk factor**

Lifestyle factor

- Obesity, in particular visceral fat
- Physical inactivity
- Malnutrition
- **Cigarette smoking**
- Extreme sleep duration

Health status

- Diabetes and its complications
- Osteoporosis
- Heart disease
- Cognitive impairment
- **Respiratory disease**
- Depression and anorexia
- Parkinson's disease

Biomarkers

- Inflammatory markers
- Blood fatty acids and vitamin D
- Adiponectin
- Pulse wave velocity
- Gut microbiota

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.metabol.2023.155533.

References

- [1] Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019;393:2636-46.
- [2] Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 2016:57:58-67
- [3] Shu X, Lin T, Wang H, Zhao Y, Jiang T, Peng X, et al. Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2022:13:145-58.
- [4] Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol 2022; 76:588-99.
- [5] Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis. J Clin Endocrinol Metab 2022:107:1470-83.
- [6] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: european consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing 2010;39: 412-23.
- [7] Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, et al. Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003;51:1602-9.
- [8] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019:48:601.
- [9] Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working Group for Sarcopenia. J Am Med Dir Assoc 2014;15:95–101.
- [10] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12:249–56.
- [11] Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014;69: 547-58.
- [12] Falcon LJ, Harris-Love MO. Sarcopenia and the new ICD-10-CM code: screening, staging, and diagnosis considerations. Fed Pract 2017;34:24-32.

- Sarcopenia
- uture directions
- High-quality cohort study
- Mendelian randomization study
- Therapeutic development

Consequence

Among patients

- ↑ Short- and long-term mortality
- ↑ Overall and severe complications
- ↑ Postoperative infection
- ↑ Prolonged hospitalization
- ↓ Survival rate

Among non-patients

- ↑ Mortality
- ↑ Cognitive impairment
- ↑ Osteoporosis, falls, and fracture
- ↑ Functional decline
- ↑ Hospitalization rate
- ↑ Metabolic syndrome and diabetes
- ↑ Nonalcoholic liver disease
- ↑ Liver fibrosis
- 个 Hypertension
- ↑ Depression
- 个 Dysphagia

Fig. 3. Summary of risk factors and consequences of sarcopenia.

- [13] Carvalho do Nascimento PR, Bilodeau M, Poitras S. How do we define and measure sarcopenia? A meta-analysis of observational studies. Age Ageing 2021;50: 1906 - 13
- [14] Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and metaanalysis, J Cachexia Sarcopenia Muscle 2022;13:86–99.
- [15] Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 2017;16:21.
- [16] Jogiat UM, Bédard ELR, Sasewich H, Turner SR, Eurich DT, Filafilo H, et al. Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2022;13: 2630-6.
- [17] Wathanavasin W, Banjongjit A, Avihingsanon Y, Praditpornsilpa K, Tungsanga K, Eiam-Ong S, et al. Prevalence of sarcopenia and its impact on cardiovascular events and mortality among dialysis patients: a systematic review and meta-analysis. Nutrients 2022;14.
- [18] Park B, Bhat S, Wells CI, Barazanchi AWH, Hill AG, MacCormick AD. Short- and long-term impact of sarcopenia on outcomes after emergency laparotomy: a systematic review and meta-analysis. Surgery 2022;172:436-45.
- [19] Surov A, Wienke A. Sarcopenia predicts overall survival in patients with malignant hematological diseases: a meta-analysis. Clin Nutr 2021;40:1155-60.
- [20] Su H, Ruan J, Chen T, Lin E, Shi L. CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. Cancer Imaging 2019;19:82.
- Sutton EH, Plyta M, Fragkos K, Di Caro S. Pre-treatment sarcopenic assessments as [21] a prognostic factor for gynaecology cancer outcomes: systematic review and metaanalysis. Eur J Clin Nutr 2022;76:1513-27.
- [22] Findlay M, White K, Stapleton N, Bauer J. Is sarcopenia a predictor of prognosis for patients undergoing radiotherapy for head and neck cancer? A meta-analysis. Clin Nutr 2021;40:1711-8.
- [23] Yang M, Shen Y, Tan L, Li W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. Chest 2019;156:101-11.
- [24] Ng ZQ, Cohen R, Misur P, Weber DG. Poorer outcomes associated with sarcopenia following emergency laparotomy: a systematic review and meta-analysis. ANZ J Surg 2022;92:3145-53.
- [25] Ibilibor C, Psutka SP, Herrera J, Rivero JR, Wang H, Farrell AM, et al. The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: a systematic review and meta-analysis. Arab J Urol 2021;19:98-103.
- Yu R, Shi Q, Liu L, Chen L. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. BMC Gastroenterol 2018;18:51.



- Multi-omics study

S. Yuan and S.C. Larsson

Metabolism xxx (xxxx) xxx

- [27] Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, et al. Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol 2020;19:245–50.
- [28] Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest 2019;156:1092–110.
- [29] Xue Q, Wu J, Ren Y, Hu J, Yang K, Cao J. Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: a systematic review and metaanalysis. BMC Geriatr 2021;21:493.
- [30] Zhang X, Huang P, Dou Q, Wang C, Zhang W, Yang Y, et al. Falls among older adults with sarcopenia dwelling in nursing home or community: a meta-analysis. Clin Nutr 2020;39:33–9.
- [31] Liu C, Wong PY, Chung YL, Chow SK, Cheung WH, Law SW, et al. Deciphering the "obesity paradox" in the elderly: a systematic review and meta-analysis of sarcopenic obesity. Obes Rev 2022;24(2):e13534.
- [32] Gao Q, Hu K, Yan C, Zhao B, Mei F, Chen F, et al. Associated factors of sarcopenia in community-dwelling older adults: a systematic review and meta-analysis. Nutrients 2021;13.
- [33] Zhang JZ, Shi W, Zou M, Zeng QS, Feng Y, Luo ZY, et al. Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2022;14(1):17–29.
- [34] Gao Q, Mei F, Shang Y, Hu K, Chen F, Zhao L, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr 2021;40: 4633–41.
- [35] Shen Y, Chen J, Chen X, Hou L, Lin X, Yang M. Prevalence and associated factors of sarcopenia in nursing home residents: a systematic review and meta-analysis. J Am Med Dir Assoc 2019;20:5–13.
- [36] Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 2017;12:835–45.
- [37] Negm AM, Lee J, Hamidian R, Jones CA, Khadaroo RG. Management of sarcopenia: a network meta-analysis of randomized controlled trials. J Am Med Dir Assoc 2022; 23:707–14.
- [38] Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817–33.
- [39] Hong SH, Bae YJ. Association between alcohol consumption and the risk of sarcopenia: a systematic review and meta-analysis. Nutrients 2022:14.
- [40] Steffl M, Bohannon RW, Petr M, Kohlikova E, Holmerova I. Alcohol consumption as a risk factor for sarcopenia - a meta-analysis. BMC Geriatr 2016;16:99.
- [41] Pourmotabbed A, Ghaedi E, Babaei A, Mohammadi H, Khazaie H, Jalili C, et al. Sleep duration and sarcopenia risk: a systematic review and dose-response metaanalysis. Sleep Breath 2020;24:1267–78.
- [42] Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcif Tissue Int 2020;107:453–63.
- [43] Ai Y, Xu R, Liu L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2021;13:93.
- [44] Li Z, Tong X, Ma Y, Bao T, Yue J. Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and metaanalysis. J Cachexia Sarcopenia Muscle 2022;13:128–44.

- [45] Ponsoni A, Sardeli AV, Costa FP, Mourão LF. Prevalence of sarcopenia in Parkinson's disease: a systematic review and meta-analysis. Geriatr Nurs 2022;49: 44–9.
- [46] Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018;15:505–22.
- [47] Pizzimenti M, Meyer A, Charles AL, Giannini M, Chakfé N, Lejay A, et al. Sarcopenia and peripheral arterial disease: a systematic review. J Cachexia Sarcopenia Muscle 2020;11:866–86.
- [48] Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol 2016;229: R67–81.
- [49] Kuchay MS, Martínez-Montoro JI, Kaur P, Fernández-García JC, Ramos-Molina B. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: an altered livermuscle crosstalk leading to increased mortality risk. Ageing Res Rev 2022;80: 101696.
- [50] Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol 2020;115:584–95.
- [51] Gao K, Cao LF, Ma WZ, Gao YJ, Luo MS, Zhu J, et al. Association between sarcopenia and cardiovascular disease among middle-aged and older adults: findings from the China health and retirement longitudinal study. EClinicalMedicine 2022;44:101264.
- [52] Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas 2017;96:10–5.
- [53] Du Y, Oh C, No J. Associations between sarcopenia and metabolic risk factors: a systematic review and meta-analysis. J Obes Metab Syndr 2018;27:175–85.
- [54] Luo J, Quan Z, Lin S, Cui L. The association between blood concentration of 25hydroxyvitamin D and sarcopenia: a meta-analysis. Asia Pac J Clin Nutr 2018;27: 1258–70.
- [55] Komici K, Dello Iacono A, De Luca A, Perrotta F, Bencivenga L, Rengo G, et al. Adiponectin and sarcopenia: a systematic review with meta-analysis. Front Endocrinol (Lausanne). 2021;12:576619.
- [56] Piotrowicz K, Klich-Rączka A, Skalska A, Gryglewska B, Grodzicki T, Gąsowski J. Pulse wave velocity and sarcopenia in older persons-a systematic review and metaanalysis. Int J Environ Res Public Health 2022;19.
- [57] Liu C, Cheung WH, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. J Cachexia Sarcopenia Muscle 2021;12:1393–407.
- [58] Hübel C, Gaspar HA, Coleman JRI, Finucane H, Purves KL, Hanscombe KB, et al. Genomics of body fat percentage may contribute to sex bias in anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet. 2019;180:428–38.
- [59] Jones G, Trajanoska K, Santanasto AJ, Stringa N, Kuo CL, Atkins JL, et al. Genomewide meta-analysis of muscle weakness identifies 15 susceptibility loci in older men and women. Nat Commun 2021;12:654.
- [60] Liu JC, Dong SS, Shen H, Yang DY, Chen BB, Ma XY, et al. Multi-omics research in sarcopenia: current progress and future prospects. Ageing Res Rev 2022;76: 101576.
- [61] Yuan S, Larsson SC. Genetically predicted insulin-like growth factor-I in relation to muscle mass and strength. Clin Endocrinol (Oxf) 2021;95:800–5.